

Consolidated Financial Statements and Supplementary Information

August 31, 2012 and 2011

(With Independent Auditors' Report Thereon)



KPMG LLP Suite 2000 303 Peachtree Street, N.E. Atlanta, GA 30308-3210

Independent Auditors' Report

The Board of Trustees Emory University:

We have audited the accompanying consolidated statements of financial position of Emory University (the University) as of August 31, 2012 and 2011, and the related consolidated statements of activities and cash flows for the years then ended. These consolidated financial statements are the responsibility of the University's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.

We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the University's internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Emory University as of August 31, 2012 and 2011, and the changes in its net assets and its cash flows for the years then ended in conformity with U.S. generally accepted accounting principles.

Our audits were conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The supplementary information included in Schedules 1 through 4 is presented for purposes of additional analysis and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audits of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the supplementary information is fairly stated in all material respects in relation to the financial statements as a whole.



January 15, 2013

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

August 31, 2012 and August 31, 2011

(Dollars in thousands)

		2012	2011		
ASSETS:				,	
Cash and cash equivalents	\$	509,994	\$	371,130	
Patient accounts receivable, net		295,061		252,047	
Student accounts receivable, net		44,207		36,778	
Loans receivable, net		26,777		27,724	
Contributions receivable, net		156,647		175,169	
Accrued investment income receivable		6,651		8,713	
Other receivables, net		244,908		245,297	
Prepaid expenses, deferred charges and other assets		190,775		151,723	
Investments		5,679,329		5,399,414	
Interests in perpetual funds held by others		1,025,848		965,613	
Property and equipment, net		2,663,442		2,428,226	
Total assets	\$	10,843,639	\$	10,061,834	
LIABILITIES AND NET ASSETS:					
Accounts payable and accrued liabilities	\$	413,338	\$	358,207	
Liability for derivative instruments		217,595		140,173	
Interest payable		27,617		22,750	
Annuities payable		18,052		19,047	
Bonds, notes and mortgages payable		1,890,733		1,788,431	
Accrued liabilities for benefit obligations and professional liabilities		391,036		243,886	
Deferred tuition and other revenue		388,913		345,362	
Deposits held in custody for others		476,915		465,776	
Government advances for federal loan programs		17,820		17,499	
Total liabilities		3,842,019		3,401,131	
Unrestricted net assets:					
Net assets controlled by Emory		2,842,668		2,787,217	
Net assets related to noncontrolling interests		61,797		(6,698)	
Total unrestricted net assets		2,904,465		2,780,519	
Temporarily restricted net assets		2,524,915		2,383,388	
Permanently restricted net assets		1,572,240		1,496,796	
Total net assets		7,001,620		6,660,703	
Total liabilities and net assets	\$	10,843,639	\$	10,061,834	

See accompanying notes to consolidated financial statements.

CONSOLIDATED STATEMENT OF ACTIVITIES

Year ended August 31, 2012 (with summarized financial information for the year ended 2011)

	Unrestricted	Temporarily Restricted	Permanently Restricted	Total August 31, 2012	Total August 31, 2011
OPERATING REVENUES:					
Tuition and fees	\$ 512,680	-	-	\$ 512,680	\$ 483,251
Less: Scholarship allowances	(183,783)	<u>-</u> _		(183,783)	(167,285)
Net tuition and fees	328,897	-	-	328,897	315,966
Endowment spending distribution	176,541	-	-	176,541	169,533
Other investment income designated for current operations	56,437	-	-	56,437	35,639
Gifts and contributions	42,639	-	-	42,639	38,169
Indirect cost recoveries	122,728	-	-	122,728	122,378
Grants and contracts	382,391	-	-	382,391	374,630
Net patient service revenue	2,418,359	-	-	2,418,359	1,999,823
Medical services	147,430	-	-	147,430	138,364
Sales and services of auxiliary operating activities	63,087	-	-	63,087	57,743
Independent operations	22,138	-	-	22,138	21,119
Patent and royalty revenue	5,760	-	-	5,760	6,819
Other revenue	87,254	-	-	87,254	81,612
Net assets released from restrictions	3,681	(3,681)	-	· -	-
Total operating revenues	3,857,342	(3,681)		3,853,661	3,361,796
OPERATING EXPENSES:					
Salaries and fringe benefits	2,304,097	_	_	2,304,097	2,039,975
Student financial aid	9,297	_	_	9,297	10,649
Other operating expenses	1,258,270	_	_	1,258,270	1,063,333
Interest on indebtedness	74,822	_	_	74,822	75,451
Depreciation Depreciation	203,110	-	_	203,110	170,727
Total operating expenses	3,849,596			3,849,596	3,360,135
	3,047,070				2,200,222
NET OPERATING REVENUES/(EXPENSES):	7,746	(3,681)		4,065	
NET OPERATING REVENUES/(EXPENSES):		(3,681)			
NET OPERATING REVENUES/(EXPENSES): NONOPERATING ACTIVITIES:	7,746		54 385	4,065	1,661
NET OPERATING REVENUES/(EXPENSES): NONOPERATING ACTIVITIES: Net unrealized gains on investments	7,746 23,945	30,445	54,385 3,032	4,065	1,661 270,769
NET OPERATING REVENUES/(EXPENSES): NONOPERATING ACTIVITIES: Net unrealized gains on investments Investment income and gains (losses) in excess of spending	7,746		54,385 3,032	4,065	1,661
NET OPERATING REVENUES/(EXPENSES): NONOPERATING ACTIVITIES: Net unrealized gains on investments Investment income and gains (losses) in excess of spending distribution for current operations	23,945 154,114	30,445 37,354	3,032	108,775 194,500	270,769 338,221
NET OPERATING REVENUES/(EXPENSES): NONOPERATING ACTIVITIES: Net unrealized gains on investments Investment income and gains (losses) in excess of spending distribution for current operations Investment management fees	23,945 154,114 (18,778)	30,445 37,354 (176)	3,032 (124)	108,775 194,500 (19,078)	270,769 338,221 (23,886
NET OPERATING REVENUES/(EXPENSES): NONOPERATING ACTIVITIES: Net unrealized gains on investments Investment income and gains (losses) in excess of spending distribution for current operations Investment management fees Gifts and contributions	23,945 154,114 (18,778) 12,241	30,445 37,354	3,032	108,775 194,500 (19,078) 103,070	270,769 338,221 (23,886 55,960
NET OPERATING REVENUES/(EXPENSES): NONOPERATING ACTIVITIES: Net unrealized gains on investments Investment income and gains (losses) in excess of spending distribution for current operations Investment management fees Gifts and contributions (Loss) gain on disposal of property and equipment	23,945 154,114 (18,778) 12,241 (11,564)	30,445 37,354 (176)	3,032 (124) 18,561	108,775 194,500 (19,078) 103,070 (11,564)	270,769 338,221 (23,886 55,960 222
NET OPERATING REVENUES/(EXPENSES): NONOPERATING ACTIVITIES: Net unrealized gains on investments Investment income and gains (losses) in excess of spending distribution for current operations Investment management fees Gifts and contributions (Loss) gain on disposal of property and equipment (Loss) gain on defeasance of debt	23,945 154,114 (18,778) 12,241 (11,564) (15,058)	30,445 37,354 (176)	3,032 (124)	108,775 194,500 (19,078) 103,070 (11,564) (15,058)	270,769 338,221 (23,886 55,960 222 2,255
NET OPERATING REVENUES/(EXPENSES): NONOPERATING ACTIVITIES: Net unrealized gains on investments Investment income and gains (losses) in excess of spending distribution for current operations Investment management fees Gifts and contributions (Loss) gain on disposal of property and equipment (Loss) gain on defeasance of debt Change in fair value of derivative instruments	23,945 154,114 (18,778) 12,241 (11,564) (15,058) (77,422)	30,445 37,354 (176) 72,268	3,032 (124) 18,561 - -	108,775 194,500 (19,078) 103,070 (11,564) (15,058) (77,422)	270,769 338,221 (23,886 55,960 222 2,255 13,370
NET OPERATING REVENUES/(EXPENSES): NONOPERATING ACTIVITIES: Net unrealized gains on investments Investment income and gains (losses) in excess of spending distribution for current operations Investment management fees Gifts and contributions (Loss) gain on disposal of property and equipment (Loss) gain on defeasance of debt Change in fair value of derivative instruments Other nonoperating items	7,746 23,945 154,114 (18,778) 12,241 (11,564) (15,058) (77,422) 48,722	30,445 37,354 (176) 72,268 - - - 5,317	3,032 (124) 18,561 - - (410)	4,065 108,775 194,500 (19,078) 103,070 (11,564) (15,058) (77,422) 53,629	270,769 338,221 (23,886 55,960 222 2,255 13,370 (3,079
NET OPERATING REVENUES/(EXPENSES): NONOPERATING ACTIVITIES: Net unrealized gains on investments Investment income and gains (losses) in excess of spending distribution for current operations Investment management fees Gifts and contributions (Loss) gain on disposal of property and equipment (Loss) gain on defeasance of debt Change in fair value of derivative instruments	23,945 154,114 (18,778) 12,241 (11,564) (15,058) (77,422)	30,445 37,354 (176) 72,268	3,032 (124) 18,561 - -	108,775 194,500 (19,078) 103,070 (11,564) (15,058) (77,422)	1,661 270,769
NET OPERATING REVENUES/(EXPENSES): NONOPERATING ACTIVITIES: Net unrealized gains on investments Investment income and gains (losses) in excess of spending distribution for current operations Investment management fees Gifts and contributions (Loss) gain on disposal of property and equipment (Loss) gain on defeasance of debt Change in fair value of derivative instruments Other nonoperating items	7,746 23,945 154,114 (18,778) 12,241 (11,564) (15,058) (77,422) 48,722	30,445 37,354 (176) 72,268 - - - 5,317	3,032 (124) 18,561 - - (410)	4,065 108,775 194,500 (19,078) 103,070 (11,564) (15,058) (77,422) 53,629	270,769 338,221 (23,886 55,960 222 2,255 13,370 (3,079
NET OPERATING REVENUES/(EXPENSES): NONOPERATING ACTIVITIES: Net unrealized gains on investments Investment income and gains (losses) in excess of spending distribution for current operations Investment management fees Gifts and contributions (Loss) gain on disposal of property and equipment (Loss) gain on defeasance of debt Change in fair value of derivative instruments Other nonoperating items Total nonoperating activities	7,746 23,945 154,114 (18,778) 12,241 (11,564) (15,058) (77,422) 48,722 116,200	30,445 37,354 (176) 72,268 - - 5,317	3,032 (124) 18,561 - - (410) 75,444	4,065 108,775 194,500 (19,078) 103,070 (11,564) (15,058) (77,422) 53,629 336,852	270,769 338,221 (23,886 55,960 222 2,255 13,370 (3,079)

See accompanying notes to consolidated financial statements.

CONSOLIDATED STATEMENT OF ACTIVITIES

Year Ended August 31, 2011

(Dollars in thousands)	Unrestricted	Temporarily Restricted	Permanently Restricted	Total August 31, 2011
OPERATING REVENUES:				
Tuition and fees	\$ 483,251	-	-	\$ 483,251
Less: Scholarship allowances	(167,285)	-	-	(167,285)
Net tuition and fees	315,966			315,966
Endowment spending distribution	169,533	-	-	169,533
Other investment income designated for current operations	35,639	-	-	35,639
Gifts and contributions	38,169	-	-	38,169
Indirect cost recoveries	122,378	-	-	122,378
Grants and contracts	374,630	-	-	374,630
Net patient service revenue	1,999,823	-	-	1,999,823
Medical services	138,364	-	-	138,364
Sales and services of auxiliary operating activities	57,743	-	-	57,743
Independent operations	21,119	_	_	21,119
Patent and royalty revenue	6,819	_	_	6,819
Other revenue	81,613	_	_	81,613
Net assets released from restrictions	5,935	(5,935)		
Total operating revenues	3,367,731	(5,935)	<u>:::::::::::::::::::::::::::::::::::::</u>	3,361,796
OPERATING EXPENSES:				
Salaries and fringe benefits	2,039,975			2,039,975
Student financial aid	10,649	-	-	10,649
Other operating expenses	1,063,333	-	-	1,063,333
Interest on indebtedness	75,451	-	-	75,451
		-	-	
Depreciation	170,727		<u> </u>	170,727
Total operating expenses	3,360,135	1:1:1:1:1:1:1:	<u> </u>	3,360,135
NET OPERATING REVENUES/(EXPENSES):	7,596	(5,935)		1,661
NONOPERATING ACTIVITIES:				
Net unrealized gains on investments	30,666	57,781	182,322	270,769
Investment income and gains (losses) in excess of spending	208,674	128,559	988	338,221
distribution for current operations				
Investment management fees	(23,557)	(168)	(161)	(23,886)
Gifts and contributions	28,675	13,492	13,793	55,960
Gain on disposal of property and equipment	222	· -		222
Gain on defeasance of debt	2,255	_	_	2,255
Change in fair value of derivative instruments	13,370	_	_	13,370
Other nonoperating items	658	(951)	(2,786)	(3,079)
Total nonoperating activities	260,963	198,713	194,156	653,832
CHANGE IN NET ASSETS	268,559	192,778	194,156	655,493
Less change in net assets related to noncontrolling interests	(4,872)	-	-	(4,872)
CHANGE IN NET ASSETS CONTROLLED BY EMORY	273,431	192,778	194,156	660,365

See accompanying notes to consolidated financial statements.

CONSOLIDATED STATEMENTS OF CASH FLOWS

Years Ended August 31, 2012 and 2011

(Dollars in thousands)

		2012		<u>2011</u>
CASH FLOWS FROM OPERATING ACTIVITIES:	\$	340,917	\$	655,493
Change in net assets	Ф	340,917	Ф	033,493
Adjustments to reconcile change in net assets to net cash				
(used in) provided by operating activities:				
Nonoperating items:				
Net assets acquired in formation of Joint Operating Company		(99,769)		-
Gain on formation of the Joint Operating Company		(18,664)		-
Gain on acquisition of joint venture		-		(35,524)
Gifts restricted for long-term investment and capital projects		(109,351)		(17,681)
Net realized gains on sale of investments		(292,706)		(408,317)
Loss (gain) on disposal of property and equipment		11,564		(222)
Interests in perpetual funds held by others		(60,235)		(184,421)
Loss (gain) on defeasance of debt		15,058		(2,255)
Noncash items:				
Depreciation		203,110		170,727
Provision for uncollectible patients accounts receivable		98,533		88,201
Accretion/amortization of bond discounts/premiums		(3,705)		(15,802)
Net unrealized gains on investments		(37,057)		(87,228)
Actuarial adjustments for retiree pension and benefit plans		52,065		(39,438)
Change in fair value of derivative instruments		77,422		(13,370)
Gifts of securities and other assets		(62,642)		(34,884)
(Increase) decrease in operating assets, net of effects from formation of Joint				
Operating Company:				
Accounts and other receivables, net		(113,233)		(186,947)
Contributions receivable		18,522		(9,604)
Accrued investment income receivable		2,062		3,790
Prepaid expenses, deferred charges and other assets		67,979		(16,915)
Increase (decrease) in operating liabilities, net of effects from formation of Joint Operating Company:				
Accounts payable, accrued liabilities and interest payable		(6,249)		55,520
Accounts payable, accrued habilities and interest payable Accrued liabilities for benefit obligations and professional liabilities		47,705		5,655
Deferred tuition and other revenue		34,923		(8,850)
Deferred tultion and other revenue		34,923		(8,830)
Net cash provided by (used in) operating activities		166,249		(82,072)
CASH FLOWS FROM INVESTING ACTIVITIES:				
Disbursements for loans to students		(3,879)		(3,204)
Repayment of loans from students		4,825		4,990
Proceeds from sales and maturities of investments		9,317,310		6,700,952
Purchases of investments		(9,204,820)		(6,320,094)
Cash received in formation of Joint Operating Company		71,953		-
Cash paid in formation of joint venture		-		(77,637)
Purchases of property, plant and equipment		(250,579)		(225,671)
Increase in deposits held in custody for others		11,139		47,703
Net cash (used in) provided by investing activities		(54,050)		127,039
				(Continued)

EMORY UNIVERSITY CONSOLIDATED STATEMENTS OF CASH FLOWS

Years Ended August 31, 2012 and 2011

(Dollars in thousands)

		<u>2012</u>		<u>2011</u>
CASH FLOWS FROM FINANCING ACTIVITIES:				
Gifts restricted for long-term investment and capital projects		109,351		17,681
Proceeds from bonds and mortgages payable		130,979		229,203
Principal repayments of bonds and mortgages payable		(172,972)		(261,907)
Required posting of collateral		(40,691)		-
Decrease in annuities payable		(995)		(213)
Increase (decrease) in government advances for federal loan programs		321		(285)
Bond issuance costs		672		(270)
Net cash provided by (used in) financing activities		26,665		(15,791)
Net increase in cash and cash equivalents		138,864		29,176
Cash and cash equivalents at beginning of year		371,130		341,954
Cash and cash equivalents at end of year	\$	509,994	\$	371,130
Supplemental disclosure:	ф	71.405	Ф	07.550
Cash paid for interest	\$	71,497	\$	87,558
Property, plant and equipment acquisitions that were reflected in accounts payable		19,399		6,064

See accompanying notes to consolidated financial statements.

Notes to Consolidated Financial Statements
August 31, 2012 and 2011

(1) Organization

Emory University (the University or Emory) is a not-for-profit corporation, located in Atlanta, Georgia, which owns and operates educational and research facilities, a healthcare system, Clifton Casualty Insurance Company Ltd. (CCIC) and Emory Medical Care Foundation (EMCF). The Emory Healthcare system (the System or Emory Healthcare) consists of (i) four general and acute care hospitals (Emory University Hospital, Emory University Hospital Midtown, EHCA Johns Creek Hospital, LLC (EJCH), and Saint Joseph's Hospital of Atlanta (SJHA)), (ii) a geriatric hospital and a long term care hospital (Wesley Woods Geriatric Hospital and Wesley Woods Long Term Care Hospital), (iii) an intermediate care nursing home (Budd Terrace), and an independent and assisted living facility for seniors (Wesley Woods Towers), (iv) three physician groups (The Emory Clinic, Inc., Emory Specialty Associates, LLC and the Medical Group at Saint Joseph's (SJMG) and one physician-group joint venture (Emory Children's Center, Inc.), (v) Emory Healthcare Corporate (EHC), and (vi) Saint Joseph's Translational Research Institute (SJTRI). The consolidated financial statements include Emory University and the aforementioned entities. All material intercompany accounts and transactions have been eliminated in consolidation.

Emory University Hospital, Emory University Hospital Midtown, EHCA Johns Creek Hospital, LLC, Saint Joseph's Hospital of Atlanta, Wesley Woods Geriatric Hospital and Wesley Woods Long Term Care Hospital are sometimes referred to herein as "the Hospitals."

Effective January 1, 2012, the System contributed EJCH to a joint operating company (JOC) under the name of Emory/Saint Joseph's, Inc. (ESJ) formed together with Saint Joseph's Health System (SJHS), in exchange for a 51% membership interest in the JOC. SJHS contributed SJHA, SJMG, SJTRI and certain other assets in exchange for its 49% membership interest in the JOC.

Included in the accounts of SJHA are Saint Joseph's Service Corporation (SJSC) and Saint Joseph's Real Estate Management, Inc. (SJRE). These for-profit subsidiaries own and operate certain assets on the Saint Joseph's Hospital campus.

(2) Summary of Significant Accounting and Reporting Policies

The following accounting policies are used in the preparation of the accompanying consolidated financial statements:

The consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (U.S. GAAP).

Net assets and revenues, gains and losses are classified based on the existence or absence of externally imposed restrictions. Accordingly, net assets of the University are classified and reported as follows:

Unrestricted Net Assets – Net assets that are not subject to externally imposed stipulations. Certain net assets classified as unrestricted are designated for specific purposes or uses under various internal operating and administrative arrangements of the University.

Temporarily Restricted Net Assets – Net assets that are subject to externally imposed stipulations that will be met either by actions of the University and/or the passage of time.

Notes to Consolidated Financial Statements August 31, 2012 and 2011

Permanently Restricted Net Assets – Net assets that are subject to externally imposed restrictions that the University maintains permanently. Generally, the donors of these assets permit the University to use all or part of the income earned and net appreciation on related investments for general or specific purposes.

Revenues are reported as increases in unrestricted net assets unless their use is limited by donor-imposed restrictions. Expenses are reported as decreases in unrestricted net assets. Gains and losses on investments and other assets or liabilities are reported as increases or decreases in unrestricted net assets unless their use is restricted by explicit donor stipulation or by law. Expirations of restrictions on net assets (i.e., the donor-stipulated purpose has been fulfilled and/or the stipulated time period has elapsed) are reported as net assets released from restrictions and shown as reclassifications between the applicable classes of net assets.

Income and realized and unrealized gains on investments of permanently restricted net assets are reported as follows:

- As increases in permanently restricted net assets if the terms of the gift require that they be added to the principal of a permanent endowment fund.
- As increases in temporarily restricted net assets until appropriated for expenditure by the University and/or donor restrictions are met.

(a) Cash Equivalents

Cash equivalents consist primarily of short-term money market mutual funds and treasury bills with original maturities of 90 days or less. These amounts are carried at cost, which approximates fair value. Cash and cash equivalents that are part of the long-term pool are shown within investments as those funds generally are not used for daily operating purposes.

(b) Contributions Receivable

Contributions of assets other than cash are recorded at their estimated fair value at the date of the gift. Contributions to be received after one year, net of an allowance for uncollectible amounts, are discounted to their present value at a risk-adjusted rate. Amortization of discounts is recorded as additional contribution revenue in accordance with donor-imposed restrictions, if any, on contributions. An allowance for uncollectible contributions receivable is provided based upon management's judgment, considering such factors as prior collection history, type of contribution, relationship with donor, and other relevant factors.

(c) Loans Receivable, Net

Emory funded loans to students are carried at estimated net realizable value. Loans receivable from students under certain governmental loan programs, carried at cost, can only be assigned to the federal government or its designees. In addition to Federal Direct Loans which do not flow through the financial statements, loans to qualified students are funded principally with government advances to Emory under the Perkins, Nursing and Health Professions Student Loan Programs.

Notes to Consolidated Financial Statements
August 31, 2012 and 2011

(d) Other Receivables, Net

Other receivables are recorded at net realizable value and include receivables under grants and contracts, medical services provided to other organizations and losses recoverable from reinsurers.

(e) Investments

Investments are reported at fair value, with the difference between fair value and cost (or fair value at date of gift) being recorded as unrealized gains (losses). The fair value of publicly traded fixed income and equity securities is based upon quoted market prices and published exchange rates, if applicable. Fair values for private partnership interests, real estate, and oil and gas properties held through limited partnerships or commingled funds, and marketable alternative investments (primarily hedge funds which are typically in the form of limited partnerships) are not as readily ascertainable and may require the use of estimates. Fair value for these investments is established based on either external events that substantiate a change in fair value or a reasonable methodology that exists to capture and quantify changes in fair value. General partners typically value privately held companies at cost or an adjusted value based on a recent arm's length transaction. Real estate partnerships and funds are valued based on appraisals of properties held and conducted by third-party appraisers retained by the general partner or investment manager. General partners of alternative investments that invest in marketable securities provide values based on quoted market prices and exchange rates for publicly traded securities and valuation estimates of derivative instruments. General partners of oil and gas partnerships also use third-party appraisers to value properties. Valuations provided by the general partners and investment managers are evaluated by the Emory Investment Management Office and are believed to present reasonable estimates of fair value at August 31, 2012 and 2011.

(f) Life Income, Gift Annuities, and Interest in Perpetual Funds Held by Others

The University's split-interest agreements with donors consist primarily of gift annuity agreements and irrevocable charitable remainder trusts for which the University serves as trustee. Assets held in the trusts are included in investments. Contribution revenues are recognized when trusts (or annuity agreements) are established, after recording liabilities for the present value of the estimated future payments to be made to beneficiaries. The liabilities are adjusted annually for changes in the value of assets, accretion of the discount, and other changes in the estimates of future benefits.

The University is also the beneficiary of certain perpetual trusts held and administered by others. The present value of the estimated future cash receipts from the trusts is recognized in beneficial interest in perpetual funds and as contribution revenue at the date such trusts are established. The carrying value of the investments is adjusted annually for changes in fair value. The fair value of these perpetual funds is recorded in the consolidated statements of financial position on August 31, 2012 and 2011 at \$1,025.8 million and \$965.6 million, respectively.

Included in these perpetual funds are the assets of the Robert W. Woodruff Health Sciences Center Fund, Inc. The Robert W. Woodruff Health Sciences Center Fund, Inc. is a tax-exempt entity established in 1996 to make grants and carry on other activities to support and benefit the Robert W. Woodruff Health Sciences Center, a division of the University which includes its medical and nursing schools, medical research laboratories and hospitals. At August 31, 2012 and 2011, the

Notes to Consolidated Financial Statements August 31, 2012 and 2011

assets of the Robert W. Woodruff Health Sciences Center Fund, Inc. were \$935 million and \$882 million, respectively. The majority of these assets are investments in the common stock of the Coca-Cola Company.

(g) Property and Equipment

Land, buildings, and equipment are recorded at cost at the date of acquisition or fair value at the date of gift to the University. Interest expense, net of interest earnings, on borrowings is capitalized during project construction periods as part of property cost. Depreciation expense is based on the straight-line method over the estimated useful lives of the assets. Useful lives are as follows: buildings -10 to 60 years; land improvements and infrastructure -5 to 40 years; moveable equipment -3 to 20 years; fixed equipment -3 to 30 years; leasehold improvements - term of the lease; and library books -10 years.

(h) Bond Issuance Costs

Costs related to the registration and issuances of bonds are being amortized over the life of the bonds on a method that approximates the effective-interest method. The costs, net of accumulated amortization, are included in prepaid expenses, deferred charges and other assets in the consolidated statements of financial position.

(i) Tuition and Fees

Tuition and fee revenues are recognized in the fiscal year during which the academic services are rendered. The accompanying consolidated statements of financial position as of August 31, 2012 and 2011 reflect deferred fall semester revenues and expenses, which will be recognized as revenues and expenditures in fiscal 2013 and 2012, respectively.

(j) Contributions Revenue

Contributions, including unconditional promises to give, are recognized as revenues in the period received. Contributions restricted for capital projects, endowment funds and contributions under split-interest agreements or perpetual trusts are reported as nonoperating revenue. All other contributions are recorded as operating revenues. Unconditional promises to give, with payments due in future periods, are recorded as increases in temporarily or permanently restricted assets at the estimated present value of future cash flows, net of an allowance for uncollectible pledges.

Donor-restricted contributions are reported as temporarily restricted or permanently restricted revenue that increases those net asset classes. Expirations of temporary restrictions on net assets, such as the donor stipulation being met or the passage of time, are reported as net assets released from restrictions and reflect reclassifications from temporarily restricted net assets to unrestricted net assets. If the donor stipulation is met in the year of the gift, the contribution is reflected in the unrestricted net asset class. Temporary restrictions on gifts to acquire long-lived assets are considered met in the period when the asset is placed in service. Conditional promises to give are not recognized until they become unconditional, that is, when the conditions on which they depend are met.

Notes to Consolidated Financial Statements
August 31, 2012 and 2011

(k) Net Patient Service Revenue

Net patient service revenue is reported at the estimated net realizable amounts from patients, third-party payors, and others for services rendered, including estimated retroactive adjustments due to future audits, reviews, and investigations. Retroactive adjustments are considered in the recognition of revenues on an estimated basis in the period the related services are rendered, and such amounts are adjusted in future periods as adjustments become known or as years are no longer subject to such audits, reviews, and investigations.

With respect to reserves for third-party payor cost report audits and anticipated settlements, the Hospitals routinely reserve 3.0 - 3.5% of relevant Medicare revenues through initial audit and settlement of related cost reports, which is then reduced to 1.0 - 1.5% of revenues until the related statutory reopening periods have expired (generally, three years from the date of initial settlement). The Hospitals have historically provided such reserves in recognition of the complexity of relevant reimbursement regulations, the volatility of related settlement processes, and an increasingly provocative overall healthcare regulatory environment, and believe that such policy properly provides for the Hospitals' routine exposures in this area consistent with industry-specific accounting principles and practices. In any event, the Hospitals' estimates in this area will differ from actual experience, and those differences may be material.

(l) Income Taxes

The University is recognized as a tax-exempt organization as defined in Section 501(c)(3) of the U.S. Internal Revenue Code (the Code) and is generally exempt from the federal income taxes on related income pursuant to Section 501(a) of the Code. Accordingly, no provision for income taxes is made in the consolidated financial statements. Unrelated business income of the University is reported on Form 990-T. As of August 31, 2012 and 2011, there were no material uncertain tax positions.

(m) Asset Retirement Obligations

The University recognizes the fair value of a liability for legal obligations associated with asset retirements in the period in which it is incurred, if a reasonable estimate of the fair value of the obligation can be made. When the liability is initially recorded, the University capitalizes the cost of the asset retirement obligation by increasing the carrying amount of the related long-lived asset. Over time, the liability is accreted to its present value each period, and the capitalized cost associated with the retirement obligation is depreciated over the useful life of the related asset. Upon settlement of the obligation, any difference between the cost to settle the asset retirement obligation and the recorded liability is recognized as a gain or loss in the consolidated statement of activities.

(n) Derivative Instruments

The University will from time to time utilize interest rate exchanges to hedge interest rate market exposure of variable rate debt. The University uses the accrual method to account for the interest rate exchanges in connection with the underlying bonds. The difference between amounts paid and received under such agreements is reported in interest expense in the consolidated statements of activities. Changes in the fair value of these exchanges are recognized as nonoperating changes in net assets in the consolidated statements of activities.

Notes to Consolidated Financial Statements
August 31, 2012 and 2011

Certain investment strategies used by the University and its investment managers incorporate various derivative financial instruments.

(o) Pension and Postretirement Benefits

The University recognizes the funded status of its defined benefit pension and postretirement benefit plans as an asset or liability and recognizes changes in funded status during the year in which the changes occur as changes in unrestricted net assets.

(p) New Accounting Pronouncements

During fiscal 2012, the University adopted the provisions of the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2010-23 (Topic 954): *Measuring Charity Care for Disclosure*. ASU 2010-23 amends Accounting Standards Codification (ASC) Subtopic 954-605, *Health Care Entities – Revenue Recognition*, to require that cost be used as the measurement basis for charity care disclosure purposes. The method used to estimate such costs as well as any funds received to offset or subsidize charity services provided should also be disclosed.

During fiscal 2012, the University adopted the provisions of FASB ASU 2010-24 (Topic 954): *Presentation of Insurance Claims and Related Insurance Recoveries*. ASU 2010-24 amends ASC Subtopic 954-450, *Health Care Entities – Contingencies*, to clarify that a health care entity should not net insurance recoveries against a related liability and that the claim liability should be determined without consideration of insurance recoveries. The adoption of ASU 2010-24 did not have a material impact on the University's consolidated financial statements.

In July 2011, FASB issued ASU 2011-07 (Topic 954): Presentation and Disclosure of Patient Service Revenue, Provision for Bad Debts, and the Allowance for Doubtful Accounts for Certain Health Care Entities. This ASU will change the University's presentation of the provision for uncollectible accounts by moving this item from operating expenses to deductions from gross patient service revenue. It also expands disclosure requirements related to policies for recognizing revenue, assessing contra revenue line items, and activity in the allowance for uncollectible accounts. The University expects to adopt this ASU in fiscal year 2013 and is currently evaluating what impact this ASU will have on the University's consolidated financial statements.

(q) Use of Estimates

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires that management make estimates and assumptions affecting the reported amounts of assets, liabilities, revenues, and expenses, as well as disclosure of contingent assets and liabilities. Actual results could differ from those estimates.

Significant items in the University's consolidated financial statements subject to such estimates and assumptions include valuations for certain investments without readily determinable fair values, the determination of the allowances for uncollectible accounts and contractual adjustments, reserves for employee healthcare and workers' compensation claims, accruals for asset retirement obligations, accrued professional and general liability costs, estimated third-party settlements, and actuarially determined benefit liabilities related to the University's pension and other postretirement benefit plans. Depreciation expense is based on the estimated useful lives of the related assets. The carrying

Notes to Consolidated Financial Statements August 31, 2012 and 2011

value of contributions to be received after one year are estimated by discounting the expected future cash flows at a risk-free rate which could have been obtained at the date of the gift.

(r) Conflict of Interest

University trustees, directors, principal officers and key employees may periodically be directly or indirectly associated with companies doing business with the University. The University requires annual disclosure of significant financial interests in, or employment or consulting relationships with, entities doing business with the University. The annual disclosures cover these key officials and their immediate family members. When such relationships exist, measures are taken to appropriately manage the actual or perceived conflict. Written conflict of interest policies for the University require, among other things, that no member of a governing board may participate in any decision in which he or she (or an immediate family member) has a material financial interest. Each board member is required to certify compliance with the conflict of interest policy on an annual basis and indicate whether the University does business with an entity in which that member (or an immediate family member) has a material financial interest. When such relationships exist, measures are taken to mitigate any actual or perceived conflict, including requiring that such transactions be conducted at arm's length, for good and sufficient consideration, based on terms that are fair and reasonable to the University, and in accordance with applicable conflict of interest laws.

(s) Reclassifications

Certain amounts previously reported have been reclassified to be consistent with the current year presentation.

(3) Contributions Receivable

Contributions receivable as of August 31 consist of the following (in thousands):

	 2012	2011
Unconditional promises expected to be collected in:		
Less than one year	\$ 59,848	18,844
One year to five years	117,744	191,222
Over five years	 5,582	10
Gross contributions receivable	183,174	210,076
Less:		
Discount to present value	(16,005)	(23,482)
Allowance for uncollectible amounts	 (10,522)	(11,425)
Contributions receivable, net	\$ 156,647	175,169

At August 31, 2012, approximately 50% of the total unconditional promises to Emory are committed by two foundations with a long-standing history of support for Emory. Contributions receivable generally are discounted at rates ranging from 2.37% to 8.75%.

Notes to Consolidated Financial Statements August 31, 2012 and 2011

The methodology for calculating an allowance for uncollectible contributions receivable is based upon management's analysis of the aging of payment schedules for all outstanding pledges over \$1 million and other factors, including donor history and quality. This review resulted in allowances for uncollectible amounts totaling 5.74% and 5.44% respectively of gross contribution receivables as of August 31, 2012 and 2011.

In November 2006, the University received a gift from the Robert W. Woodruff Foundation, Inc. for \$240 million to support the University's future Healthcare facility projects. As of August 31, 2012, \$160 million had been received with the remaining \$80 million reported in contributions receivable and temporarily restricted net assets.

As of August 31, 2012, the University had received bequest intentions of approximately \$128 million. These intentions to give are not recognized as assets or revenues and, if received, will generally be restricted for purposes stipulated by the donor.

(4) Business and Credit Concentrations

The System grants credit to patients, substantially all of whom reside in the southeastern United States. The System generally does not require collateral or other security in extending credit to patients; however, it routinely obtains assignment of (or is otherwise entitled to receive) patients' benefits payable under their health programs, plans, or policies (e.g. Medicare, Medicaid, Blue Cross, and other preferred provider arrangements and commercial insurance policies). The mix of net receivables from patients and third-party payors follows:

		2011
Managed care and other third-party payors	61%	53%
Medicare	29	34
Patients	5	8
Medicaid	5	5
	100%	100%

2012

2011

(5) Net Patient Service Revenue

The System has agreements with governmental and other third-party payors that provide for reimbursement to the System at amounts different from established rates. Contractual adjustments under third-party reimbursement programs represent the difference between the System's billings at established rates for services and amounts reimbursed by third-party payors. A summary of the basis of reimbursement with major third-party payors follows:

Medicare – Substantially all acute care and professional services rendered to Medicare program
beneficiaries are paid at prospectively determined rates. These rates vary according to patient
classification systems that are based on clinical, diagnostic, and other factors. Certain types of
exempt services and other defined payments related to Medicare beneficiaries are paid based upon
cost reimbursement or other retroactive-determination methodologies. The System is paid for

Notes to Consolidated Financial Statements
August 31, 2012 and 2011

retroactively determined items at tentative rates, with final settlement determined after submission of annual cost reports by the System and audits by the Medicare fiscal intermediary. The System's cost reports have been audited and substantially settled for all fiscal years through August 31, 2006. Revenues from the Medicare program accounted for approximately 36% and 31% of the System's net patient service revenue for the years ended August 31, 2012 and 2011, respectively.

• Medicaid – Inpatient and professional services rendered to Medicaid program beneficiaries are paid at prospectively determined rates. Outpatient services are generally paid based upon cost reimbursement methodologies. The System's cost reports have been audited and substantially settled for all fiscal years through August 31, 2006. Revenues from the Medicaid program accounted for approximately 3% of the System's net patient service revenue for both the years ended August 31, 2012 and 2011. The System contracts with certain managed care organizations in providing services to Medicaid beneficiaries. Payment arrangements with these managed care organizations consist primarily of prospectively determined rates per discharge, discounts from established charges, or prospectively determined per diem rates.

The System has also entered into other reimbursement arrangements providing for payment methodologies which include prospectively determined rates per discharge, discounts from established charges, and prospectively determined per diem rates.

The composition of net patient service revenue follows (in thousands):

	_	2012	2011
Gross patient service revenue Less provisions for contractual and other adjustments	\$	6,043,651 (3,625,292)	4,667,156 (2,667,333)
Net patient service revenue	\$	2,418,359	1,999,823

2012

2011

In the spring of 2010, the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act (collectively, the Health Care Acts) were signed into law. The impact of the Health Care Acts is complicated and difficult to predict, but the System anticipates its reimbursement in the future will be affected by major elements of the Health Care Acts designed to (1) increase insurance coverage, (2) change provider and payor behavior, and (3) encourage alternative delivery models. Many healthcare reform variables remain unknown and are, among other things, dependent on implementation by federal and state governments and reactions by providers, payors, employers, and individuals. The System continues to monitor developments in healthcare reform and participates actively in contemplating and designing new programs that are encouraged and/or required by the Health Care Acts.

Notes to Consolidated Financial Statements August 31, 2012 and 2011

(6) Investments

The following table summarizes the fair value of investments as of August 31 (in thousands): 2011 2012 Short term investments and cash equivalents (a) 348,299 228,763 Fixed income securities: U.S. government securities (b) 392,853 423,138 Domestic bonds and long-term notes (c) 717,119 622,857 International bonds and long-term notes (d) 214,389 221,724 U.S. equity securities (e) 434,245 663,929 Non-U.S. equity securities (f) 597,424 633,548 Natural resources (g) 398,618 317,874 Private markets (h) 1,204,749 1,127,163 Hedged strategies (i,j,k) 1,078,474 891,345 Real estate investments (1) 286,633 266,451 Miscellaneous investments (m) 3,216 3,026 Total investments at fair value 5,676,019 5,399,818 Joint ventures (equity method) 3,310 (404)Total investments 5,679,329 5,399,414

- (a) Includes short-term U.S. Treasury securities with maturities of less than one year and other short-term, highly liquid debt securities, as well as funds that invest in these types of investments. At August 31, 2012 and 2011, \$27.4 million was posted as collateral and thus not readily available for use.
- (b) Includes investments in U.S. Treasury and agency debt securities with maturities of more than one year and funds that invest in these types of investments.
- Includes investments in non-government debt securities with maturities of more than one year. Investments consist primarily of credit-oriented securities including U.S. investment-grade and below investment-grade debt securities. Other investments include mortgage-backed securities, asset-backed securities, repurchase agreements, senior loans, and bank loans.
- Includes investments in funds that invest in non-U.S. government debt securities with maturities of more than one year and funds that invest in these types of investments. Fund managers have the ability to shift investments from non-U.S. developed to emerging markets. The fair values of some of the fund investments in this category have been estimated using the net asset value per share of the investments.
- (e) Includes investments in U.S. common stocks and funds that invest primarily in U.S. common stocks and S&P 500 futures. Fund managers have the ability to shift investments from value to growth strategies and from small capitalization to large capitalization stocks. The fair values of some of the fund investments in this category have been estimated using the net asset value per share of the investments.

Notes to Consolidated Financial Statements August 31, 2012 and 2011

- Includes investments in non-U.S. common stocks and funds that invest primarily in non-U.S. common stocks. Fund managers have the ability to shift investments from value to growth strategies, from small capitalization to large capitalization stocks, and from developed non-U.S. markets to emerging markets. The fair values of some of the investments in this category have been estimated using the net asset value per share of the investments.
- Includes illiquid investments in timber, mining, energy, commodities and related services businesses held in commingled limited partnership funds. The nature of the investments in this category is such that distributions are received through liquidation of the underlying assets of the funds. It is estimated that the underlying assets of the funds will be liquidated over the next 6 to 12 years. Also includes marketable inflation hedging assets.
- (h) Includes illiquid investments in venture capital, growth equity, buyout, mezzanine, and distressed debt held in commingled limited partnership funds. The nature of the investments in this category is such that distributions are received through liquidation of the underlying assets of the funds. It is estimated that the underlying assets of the funds will be liquidated over the next 4 to 8 years.
- (i) Includes investments in hedge funds that pursue multiple strategies to diversify risks and reduce volatility. The hedge fund composite portfolio includes common stocks, credit-oriented securities and arbitrage investments. Fund managers have the ability to shift investments across strategies and from a net long position to a net short position. These funds generally have a low net long position. The fair values of the fund investments in this category have been estimated using the net asset value per share of the investments.
- Includes long and short investments in U.S. and non-U.S. hedge funds that invest both long and short primarily in U.S. and non-U.S. common stocks. Fund managers have the ability to shift investments from value to growth strategies, from small capitalization stocks to large capitalization stocks, from U.S. to non-U.S. stocks, and from a net long position to a net short position. These funds generally have a low net long position. The fair values of the fund investments in this category have been estimated using the net asset value per share of the investments.
- Includes various single or multi strategy hedge fund investments that invest both long and short primarily in U.S. equities, non-U.S. equities, commodities, and fixed income and can include the use of derivatives. The fair values of the fund investments in this category have been estimated using the net asset value per share of the investments.
- Includes illiquid investments in real estate assets, projects, or land held in commingled limited partnership funds. The fair value of these investments is calculated from the net asset value of Emory's ownership interests in these funds. The nature of the investments in this category is such that distributions are received through liquidation of the underlying assets of the funds. It is estimated that the underlying assets of the funds will be liquidated over the next 5 to 10 years.
- (m) Includes other investments in mutual funds not included in the endowment and other similar funds.

At August 31, 2012 and 2011, cash equivalents of \$327.0 million and \$199.3 million, respectively, are included in investments and restricted for use by endowments and special projects.

The University's investment policies allow certain fund managers to use forward exchange contracts, currency hedges, and exchange agreements in order to reduce the volatility and manage market risk

Notes to Consolidated Financial Statements
August 31, 2012 and 2011

involved in its investment portfolio. These financial instruments are included in investments at fair value in the accompanying consolidated statements of financial position with the related gain or loss recognized as investment income and gains (losses) in excess of spending distributions for current operations in the accompanying consolidated statements of activities.

Investment securities are exposed to several risks, such as interest rate, currency, market, and credit risks. Management continues to monitor the composition of its portfolio to assess the potential impact of market conditions on the valuation of its investments.

Liquidity risk represents the possibility that the University may not be able to rapidly adjust the size of its portfolio holdings in times of high volatility and financial stress at a reasonable price. If the University was forced to dispose of an illiquid investment at an inopportune time, it might be forced to do so at a substantial discount to fair value. The University invests in alternative investments, some of which can be highly illiquid. Under adverse market or economic conditions, the secondary market for certain of these alternative investments could contract further. As a result, the University could find it more difficult to sell these securities or may only be able to sell the securities at prices lower than if such securities were widely traded.

The University may hold investments denominated in currencies other than the U.S. dollar. Thus, there is exposure to currency risk because the value of the investments denominated in other currencies may fluctuate due to changes in currency exchange rates, and this can have an effect on the reported value of these investments.

The value of securities held by the University may decline in response to certain economic events, including those events impacting entities whose securities are owned and included in the investment portfolio. Those events impacting valuation may include (but are not limited to) economic changes, market fluctuations, regulatory changes, global and political instability, and currency, interest rate, and commodity price fluctuations. The University attempts to manage this risk through diversification, ongoing due diligence of fund managers, and monitoring of economic conditions.

Management is required to make certain estimates in the preparation of the consolidated financial statements. Among those potentially significant estimates are the valuation of private market investments, real estate, oil and gas properties, and certain alternative investments that invest in marketable securities. Because these investments are not readily marketable, the estimated value is subject to uncertainty and, therefore, may differ from the value that would have been used had a ready market for the investments existed and such differences could be material. Management's estimates are subjective and require judgment regarding significant matters such as the amount and timing of future cash flows and the selection of discount rates that appropriately reflect market and credit risks. The University believes that the carrying amounts of these investments are a reasonable estimate of fair value. Estimates, by their nature, are based on judgment and available information. Changes in assumptions could have a material impact on the consolidated financial statements.

Notes to Consolidated Financial Statements
August 31, 2012 and 2011

As of August 31, 2012, the estimated fair value of the University's alternative investments, the related unfunded commitments and limitations and restrictions on the University's ability to redeem or sell are summarized as follows (in thousands):

	_	2012	Unfunded commitments	Redemption frequency (if currently eligible)	Redemption notice period
Hedged strategies	\$	1,078,474	124,064	30 – over 365 days	5 – 180 days
Natural resources		398,618	61,183	N/A	N/A
Real estate investments		286,633	19,836	N/A	N/A
Private market investments	_	1,204,749	242,667	N/A	N/A
	\$_	2,968,474	447,750		

Over the next five years, approximately 95% of the unfunded commitments are expected to be called by the general partners. Although the University is obligated to fund these commitments, many of these agreements allow resale. Funds to meet these commitments will be required over future years and are expected to be generated from existing endowment assets.

(7) Endowment Net Assets

The University's Endowment (Endowment) consists of approximately 1,600 individual funds established for a variety of purposes including both donor-restricted endowment funds and funds designated by the Board of Trustees to function as endowments. The Endowment provides stable financial support to a wide variety of programs and activities in perpetuity, playing a critical role in enabling the university to achieve its mission. Net assets associated with these endowment funds are classified and reported based on the existence or absence of donor-imposed restrictions.

(a) Interpretation of Relevant Law

The Board of Trustees of the University has approved the University's adoption of the State of Georgia Uniform Prudent Management of Institutional Funds Act (UPMIFA) which provides standards for managing investments of institutional funds and spending from endowments. The University classifies as permanently restricted net assets (a) the original value of gifts donated to the permanent endowment, (b) the original value of subsequent gifts to the permanent endowment, and (c) accumulations to the permanent endowment made in accordance with the direction of the applicable donor gift instrument at the time the accumulation is added to the fund.

Notes to Consolidated Financial Statements August 31, 2012 and 2011

The remaining portion of the donor-restricted endowment fund that is not classified in permanently restricted net assets is classified as temporarily restricted net assets until those amounts are appropriated for expenditures by the University in a manner consistent with the standard of prudence prescribed by the Act. In accordance with the Act, the University considers the following factors in making a determination to appropriate or accumulate donor-restricted endowment funds:

- 1. The duration and preservation of the fund
- 2. The purposes of the University and the donor-restricted endowment fund
- 3. General economic conditions
- 4. The possible effect of inflation and deflation
- 5. The expected total return from income and the appreciation of investments
- 6. Other resources of the University
- 7. The investment policies of the University

The endowment funds subject to UPMIFA are true endowments and do not include perpetual trusts and endowments held by others, long-term investments, annuity funds, and deposits held in custody and miscellaneous investments. Endowment funds are categorized in the following net asset classes as of August 31 (in thousands):

	20	12	 20)11
	Donor- Restricted	Board- Designated	Donor- Restricted	Board- Designated
Unrestricted Temporarily restricted Permanently restricted	\$ (30,265) 2,180,307 586,627	1,316,780 — —	\$ (31,426) 2,114,142 568,335	1,316,233 — —
Total endowment funds	\$ 2,736,669	1,316,780	\$ 2,651,051	1,316,233

Notes to Consolidated Financial Statements August 31, 2012 and 2011

Changes in endowment funds by net asset classification for the years ended August 31 are summarized as follows (in thousands):

	2012				
	Unrestricted	Temporarily Restricted	Permanently Restricted	Total	
Endowment net assets,					
beginning of year \$	1,284,807	2,114,142	568,335	3,967,284	
Investment return:					
Investment income	179,203	96,940	_	276,143	
Net appreciation (depreciation)	(9,627)	29,654		20,027	
Total investment					
return	169,576	126,594	_	296,170	
Contributions	595	44	18,292	18,931	
Appropriation for expenditure (1)	(131,929)	(60,473)	_	(192,402)	
Transfers from board-designated					
funds for strategic initiatives	(36,534)			(36,534)	
Endowment net assets,					
end of year \$	1,286,515	2,180,307	586,627	4,053,449	

⁽¹⁾ Approprations for current operations are reflected in operating return and the remainder is included in nonoperating activities.

		2011			
		Unrestricted	Temporarily Restricted	Permanently Restricted	Total
Endowment net assets,					
beginning of year	\$	1,151,198	1,928,802	555,800	3,635,800
Investment return:					
Investment income		190,026	191,405	_	381,431
Net appreciation		55,211	56,041		111,252
Total investment					
return		245,237	247,446	_	492,683
Contributions		17,736	15	12,535	30,286
Appropriation for expenditure (1)		(128,189)	(62,121)	_	(190,310)
Transfers from board-designated funds for strategic initiatives	•	(1,175)			(1,175)
Endowment net assets, end of year	\$	1,284,807	2,114,142	568,335	3,967,284

⁽¹⁾ Approprations for current operations are reflected in operating return and the remainder is included in nonoperating activities.

Notes to Consolidated Financial Statements
August 31, 2012 and 2011

(b) Funds with Deficiencies

From time to time, the fair value of assets associated with individual donor-restricted endowment funds may fall below the level of the donor's original contribution. Deficiencies of this nature that are reported in unrestricted net assets were \$30.3 million and \$31.4 million as of August 31, 2012 and 2011, respectively. Subsequent gains that restore the fair value of the assets of the endowment fund to book value will be classified as an increase in unrestricted net assets.

(c) Return Objectives and Risk Parameters

The University has adopted investment and spending policies for endowment assets that attempt to provide a predictable stream of funding to programs supported by its endowment while seeking to maintain the purchasing power of the endowment assets. Under this policy, as approved by the Board of Trustees, the endowment assets are invested in a manner to attain a total return of at least 8% (including inflation) over the long term. Over shorter time periods, the endowment assets performance will be measured versus a policy benchmark. The policy benchmark represents the weighted average of benchmark returns to each asset class in the policy asset allocation. The performance objective is to outperform the policy benchmark by at least 50 basis points net of fees, on average. It is not expected that the performance target will be met for every three-year period.

(d) Strategies Employed for Achieving Objectives

To satisfy its long-term rate-of-return objectives, the University relies on a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized) and current yield (interest and dividends). The University employs a diversified asset allocation strategy across global equities, fixed income, marketable alternatives, and private investment to achieve its long-term return objectives within prudent risk constraints. The Endowment's long-term target asset allocation is approved by the Investment Committee of the Board of Trustees. The portfolio is periodically rebalanced to the target weightings for each asset class.

(e) Relationship between Investment Objectives and Spending Policy

The University's Board of Trustees has established a spending policy that determines how endowment distributions are made. The University employs a total return endowment spending policy that establishes the amount of endowment investment return available to support current operating and capital needs. The distribution of endowment income in 2012 and 2011 was based on 4.75% of the average fair value of the endowment over the previous 12 months ending on December 31. The University considers the expected return on its endowment, including the effect of inflation in setting the annual appropriation amount. Accordingly, the University expects the current spending policy to allow its endowment to maintain its purchasing power if projected growth rates are achieved. Additional real growth will be provided through new gifts and any excess investment return. The payout rate is approved annually by the Board of Trustees as part of the budget process.

(8) Derivative Instruments and Hedging Activities

The University has executed derivative financial instruments in the normal course of its business.

Notes to Consolidated Financial Statements
August 31, 2012 and 2011

As a component of the debt portfolio, the University entered into interest rate swap agreements that effectively convert certain variable rate debt to fixed rates.

The following table summarizes the general terms for each of the University's exchange agreements as of August 31, 2012 (dollars in thousands):

Type	Effective date	Notional amount	University pays	University receives
Basis (1)	08/04/2005	250,000	68% of 3-month	SIFMA Muni Swap Index
			LIBOR plus 0.36%	less 0.05%
Interest	08/04/2005	250,000	3.238%	68% of 3-month LIBOR
Interest	08/23/2005	80,000	3.255%	68% of 3-month LIBOR
Interest	04/19/2007	9,910	4.388%	68% of 3-month LIBOR
Interest	12/01/2007	75,000	3.549%	68% of 3-month LIBOR
Interest	05/01/2008	75,000	3.607%	68% of 3-month LIBOR
Interest	12/01/2008	100,000	3.286%	68% of 3-month LIBOR
Interest	12/01/2009	75,000	3.583%	68% of 3-month LIBOR

⁽¹⁾ Expired on September 1, 2011.

Net settlement transactions related to the exchange agreements described above resulted in interest expense totaling \$20.1 million and \$21.6 million during 2012 and 2011, respectively. The fair value of each exchange agreement is the estimated amount the University would receive or pay to terminate the exchange agreement at the reporting date, taking into account current interest rates and the current credit worthiness of the exchange counterparties. The University's exchange agreements are categorized as Level 2 in the fair value hierarchy. The University's exchange arrangements are exposed to credit loss in the event of nonperformance by the counterparty and to interest rate risk driven by factors influencing the spread between the taxable and tax-exempt market interest rates on its basis exchange. The University monitors the credit standing of its counterparties.

Certain University derivative instruments contain provisions requiring long-term, unsecured debt to be maintained at specified credit ratings from Moody's Investor Service and Standard and Poor's Rating Service. If the ratings of the University's debt were to fall below certain benchmarks, the counterparty could request immediate payment on derivatives in net liability positions. At August 31, 2012, the University's long-term debt ratings exceeded these benchmarks.

The aggregate fair value of all derivative instruments with credit-risk related contingent features that are in a liability position is \$217.6 million and \$140.2 million on August 31, 2012 and 2011, respectively, for which Emory University had a requirement to post collateral in the amount of \$40.7 million for 2012. There was no requirement to post collateral on August 31, 2011.

Notes to Consolidated Financial Statements August 31, 2012 and 2011

The following table summarizes the derivatives not designated as hedging instruments as of August 31 (in thousands):

		20	12	20	11
	•	Fair value ⁽¹⁾	Gain (loss) ⁽²⁾	Fair value ⁽¹⁾	Gain (loss) ⁽²⁾
August 4, 2005 Interest Rate	-				
Śwap	\$	(72,492)	(26,569)	(45,923)	4,240
August 4, 2005 Basis Swap (3)		_	92	(92)	659
August 23, 2005 Interest Rate					
Swap		(23,808)	(8,825)	(14,983)	1,720
April 19, 2007 Interest Rate		(2.77A)	(2.77.t)		
Swap		(2,554)	(2,554)	_	_
December 1, 2007 Interest Rate		(26.470)	(0.445)	(19.024)	1 505
Swap May 1, 2008 Interest Rate		(26,479)	(8,445)	(18,034)	1,505
Swap		(29,489)	(9,357)	(20,132)	1,698
December 1, 2008 Interest Rate		(2),40)	(),331)	(20,132)	1,000
Swap		(35,498)	(13,562)	(21,936)	2,595
December 1, 2009 Interest Rate		, ,	, ,	, ,	,
Swap	_	(27,275)	(8,202)	(19,073)	953
	\$	(217,595)	(77,422)	(140,173)	13,370

⁽¹⁾ Reported as liability for derivative instruments on the consolidated Statement of Financial Position.

Emory is exposed to interest rate risk driven by factors influencing the spread between the taxable and tax-exempt market interest rates on its basis swap.

Emory is exposed to financial loss in the event of nonperformance by counterparty to any of the financial instruments described above. General market conditions could impact the credit standing of the counterparties and, therefore, potentially impact the value of the instruments on Emory's consolidated statement of financial position. Emory controls this counterparty credit risk by considering the credit rating, business risk, and reputation of any counterparty before entering into a transaction, monitoring for any change in the credit standing of its counterparty during the life of the transaction, and requiring collateral be posted when predetermined thresholds are crossed.

Investment strategies employed by Emory and investment managers retained by Emory may incorporate the use of various derivative financial instruments with off balance sheet risk. Emory uses these instruments for a number of investment purposes, including hedging or altering exposure to certain asset classes and cost-effectively adding exposures to portions of the portfolio.

The fair value of derivative instruments included in investments is a net \$39.7 million asset and a net \$21.5 million liability as of August 31, 2012 and 2011, respectively, with the value primarily comprised of

⁽²⁾ Reported in nonoperating activities as change in fair value of derivative instruments.

⁽³⁾ Expired on 9/1/2011.

Notes to Consolidated Financial Statements
August 31, 2012 and 2011

futures. The net gain of \$84 million and \$12.6 million associated with the derivatives is reflected in nonoperating activities in fiscal 2012 and 2011, respectively. The definition of these and other derivative instruments entered into by Emory or its external investment managers on its behalf are as follows:

- (a) Forward contracts with various counterparties to obtain exposure to foreign currency exchange rate movements, and in other cases, to hedge against certain foreign currency exchange rate risks resulting from non-U.S. dollar denominated investment securities. Forward contracts are contracts in which the seller agrees to exchange specified currencies on a specified date at a specified rate or to make cash settlement for the value of the agreement at expiration. Risks associated with forward currency contracts are the inability of counterparties to meet the terms of their contracts and movements in exchange rates. Gains and losses on forward transactions are recorded based on changes in fair value. Emory has established procedures to actively monitor and manage market and credit risks.
- **(b) Futures contracts** to hedge exposure to equity price and interest rate movements and to obtain exposure to movements in the exchange rates of certain currencies, prices of certain commodities, and equities prices. Futures contracts are agreements in which the seller agrees to either make delivery of specified assets on a specified future date at a specified price or make cash settlement for the value of the agreement at expiration. Emory's maximum loss exposure for purchased contracts is the notional value of the contracts. Emory has unlimited liability on contracts sold. Emory has established procedures to actively monitor and manage market and credit risks.

The purchase and sale of futures contracts requires margin deposits with a Futures Commission Merchant (FCM). The Commodity Exchange Act requires an FCM to segregate all customer transactions and assets from the FCM's proprietary activities. A customer's cash and other equity deposited with an FCM are considered commingled with all other customer funds subject to the FCM's segregation requirements. In the event of an FCM's insolvency, recovery may be limited to Emory's pro rata share of segregated customer funds available. It is possible that the recovery amount could be less than the total of cash and other equity deposited.

Swap agreements, including equity, index, interest rate, credit default, option, and variance swaps as part of its investment strategies to gain exposure to and, in some cases, hedge against changes in stock prices, interest rate levels, credit strength of specified companies, and market volatility. Generally, a swap contract is an agreement that obligates two parties to exchange a series of cash flows at specified intervals based upon, or calculated by, reference to changes in specified prices or rates for a specified notional amount of the underlying assets. The payment flows are usually netted against each other, with the difference, subject to a predetermined threshold limit, being paid by one party to the other. During the term of the swap contracts, changes in value are recognized as unrealized gains or losses by marking the contracts to market. Emory records a realized gain or loss when periodic payments are received or made. A loss may result from the failure of the counterparty to the swap contract failing to comply with the terms of the swap contract. Such loss is generally limited to the aggregate of the unrealized gain on the swap contract less collateral held or plus any collateral posted with the counterparty. Emory considers the creditworthiness of its swap contract counterparties in evaluating potential credit risk. Additionally, risks may arise from unanticipated movements in the fair value of the underlying securities and the lack of market liquidity to unwind the positions at current fair values.

Notes to Consolidated Financial Statements
August 31, 2012 and 2011

(d) Option contracts (including swaptions, which are options on swaps) to obtain exposure to price movements of certain financial instruments and as economic hedges against certain equity positions held in its portfolio. Purchased option contracts give Emory the right, but not the obligation, to buy or sell within a limited time, a financial instrument, commodity, or currency at a contracted price. Option contracts may also be settled in cash, based on the difference between the contracted price and market price at the exercise date. The value of an option has two components: time value and intrinsic value. An option expires on a certain date and as the expiration date approaches, the time value of an option will decline. In addition, if the stock underlying the option declines in price, the intrinsic value of an "in the money" option will decline. Further, if the price of the stock underlying the option does not exceed the strike price of the option on the expiration date, the option will expire worthless. As a result, there is the potential for Emory to lose its entire investment in an option.

Options written (sold) by Emory obligate Emory to buy or sell within a limited time, a financial instrument, commodity, or currency at a contracted price. Alternatively, Emory can settle in cash, based on the difference between the contracted price and market price at the exercise date. All options expose Emory to market risk for changes in the financial instrument underlying the written option.

Emory is exposed to counterparty risk in that the seller of an option contract might not sell or purchase the underlying asset as agreed under the terms of the option contract. The maximum exposure to loss from counterparty risk for Emory is the fair value of the contracts and the premiums paid to purchase its open option contracts. Emory considers the creditworthiness of the intermediary counterparty to its option transactions in evaluating potential credit risk.

- (e) Transactions where Emory received rights from its portfolio companies upon an investment in a debt or equity of a company. The rights provide Emory with exposure, and potential gains from, depreciation or appreciation of the portfolio company's share price. Rights entitle the holder to buy stock of the issuing company at a specified price. Changes in the value of the rights are recognized as unrealized gains or losses by at the end of each day's trading. If the right is exercised, the new stock is assigned a cost basis at the strike price and the right is marked to zero. If the right is sold, Emory records a realized gain or loss.
- (f) Transactions where Emory received warrants from its portfolio companies upon an investment in the debt or equity of a company. The warrants provide Emory with exposure and potential gains upon appreciation of the portfolio company's share price.

The value of a warrant has two components: time value and intrinsic value. A warrant expires on a certain date and as that date approaches, the time value of a warrant will decline. In addition, if the stock underlying the warrant declines in price, the intrinsic value of an "in the money" warrant will decline. Further, if the price of the stock underlying the warrant does not exceed the strike price of the warrant on the expiration date, the warrant will expire worthless. As a result, there is the potential for Emory to lose its entire investment in a warrant.

Emory is exposed to counterparty risk in that the issuer of warrants may fail to settle its exercised warrants. The maximum loss from counterparty risk for Emory is the fair value of the contracts and

Notes to Consolidated Financial Statements
August 31, 2012 and 2011

the purchase price of the warrants. Emory considers the effects of counterparty risk when determining the fair value of its investments in warrants.

(9) Fair Values of Assets and Liabilities

The carrying values for cash and cash equivalents, patient receivables, short-term receivables, and short-term payables approximate fair value because of the terms and relative short maturity of these financial instruments. Contributions receivable and annuity and other split-interest obligations carrying amounts approximate fair value because these instruments are recorded at estimated net present value. Long-term investments and deposits held in custody for others are reflected in the accompanying consolidated financial statements at fair value. It is not practicable to determine the fair value of loans receivables, comprised primarily of federally sponsored student loans, and government advances for federal loan programs due to significant government restrictions as to marketability, interest rates, and repayment terms of these loans. The estimated fair value of the University's long-term debt, based on the quoted market prices for issues with similar terms and maturities, is approximately \$1.8 billion at August 31, 2012 and 2011. The fair value of fixed and variable rate debt maturities is determined by each bond's par amount outstanding multiplied by its price on an actively traded market. The carrying value of long-term debt reflected in the accompanying consolidated statements of financial position is approximately \$1.9 billion and \$1.8 billion at August 31, 2012 and 2011, respectively.

Assets and liabilities measured and reported at fair value are classified and disclosed within one of the following categories:

Level 1 – Valuations for assets and liabilities traded in active exchange markets as of the reporting date. Valuations are obtained from readily available pricing sources for market transactions involving identical assets or liabilities. The type of investments in Level 1 includes listed equities held in the name of the University, and excludes listed equities and other securities held indirectly through commingled funds.

Level 2 – Valuations are determined through direct or indirect observations other than quoted market prices. The type of investments in Level 2 includes those in which the University is a unit of account holder within a fund that holds underlying assets that are traded in active exchange markets with readily available pricing, except those which, as a practical expedient, are carried at NAV as reported by investment managers.

Level 3 – Valuations for assets and liabilities that are derived from other valuation methodologies including discounted cash flow models and similar techniques, and not based on market exchange, dealer, or broker-traded transactions. Level 3 valuations incorporate certain assumptions and projections in determining the fair value assigned to such assets or liabilities and, as a practical expedient, are carried at NAV as reported by investment managers.

Notes to Consolidated Financial Statements August 31, 2012 and 2011

The following table summarizes the valuation of the University's assets and liabilities according to the fair value hierarchy levels as of August 31, 2012 (in thousands):

		Total	Fair value hierarchy		
	_	fair value	Level 1	Level 2	Level 3
Financial assets:					
Investments:					
Short-term investments and					
cash equivalents	\$	348,299	102,318	245,981	_
Fixed income securities:					
U.S. government					
securities		392,853	68,447	324,406	_
Domestic bonds and					
long term notes		717,119	343,903	373,181	35
International bonds and					
long term notes		214,389	(11)	214,400	_
U.S. equity securities		434,245	203,528	230,714	3
Non-U.S. equity securities		597,424	330,426	266,998	_
Natural resources		398,618	_	_	398,618
Private market investments		1,204,749	_	_	1,204,749
Hedged strategies		1,078,474	_	304,198	774,276
Real estate investments		286,633	78,341	5,025	203,267
Miscellaneous investments	_	3,216	3,216		
Total investments (1)		5,676,019	1,130,168	1,964,903	2,580,948
Interest in perpetual funds held					
by others	_	1,025,848		<u> </u>	1,025,848
Total assets (1)	\$_	6,701,867	1,130,168	1,964,903	3,606,796
Financial liabilities:					
Derivative instruments -					
interest rate swaps		(217,595)	_	(217,595)	_
Deposits held in custody					
for others	_	(476,915)		(476,915)	
Total liabilities	\$_	(694,510)		(694,510)	

⁽¹⁾ Certain investments in joint ventures carried under the equity method of accounting are not reported at fair value and thus not included in the table above.

Notes to Consolidated Financial Statements August 31, 2012 and 2011

The following table summarizes the valuation of the University's assets and liabilities according to the fair value hierarchy levels as of August 31, 2011 (in thousands):

Financial assets: Investments Level 1 Level 2 Level 3 Financial assets: Investments and cash equivalents \$ 228,763 228,357 406 — Fixed income securities: U.S. government securities Securities 423,138 — 423,138 — Domestic bonds and long term notes 622,857 194,229 428,605 23 International bonds and long term notes 221,724 — 221,724 — U.S. equity securities 663,929 382,041 281,885 3 Non-U.S. equity securities 663,929 382,041 281,885 3 Natural resources 317,874 — 2021,724 — Natural resources 317,874 — 219,328 672,017 Real estate investments 1,127,163 — 219,328 672,017 Real estate investments 3,026 3,026 — — <td cols<="" th=""><th></th><th></th><th>Total</th><th colspan="3">Fair value hierarchy</th></td>	<th></th> <th></th> <th>Total</th> <th colspan="3">Fair value hierarchy</th>			Total	Fair value hierarchy		
Investments: Short-term investments and cash equivalents \$ 228,763 228,357 406 —			fair value	Level 1	Level 2	Level 3	
Short-term investments and cash equivalents \$ 228,763 228,357 406 —	Financial assets:		_				
cash equivalents \$ 228,763 228,357 406 — Fixed income securities: U.S. government Fixed income securities 423,138 — 423,138 — Domestic bonds and long term notes 622,857 194,229 428,605 23 International bonds and long term notes 221,724 — 221,724 — U.S. equity securities 663,929 382,041 281,885 3 Non-U.S. equity securities 633,548 274,633 358,915 — Natural resources 317,874 — — 317,874 Private market investments 1,127,163 — — 1,127,163 Hedged strategies 891,345 — 219,328 672,017 Real estate investments 266,451 59,240 4,233 202,978 Miscellaneous investments 3,026 3,026 — — Total investments 5,399,818 1,141,526 1,938,234 2,320,058 Interest in perpetual funds held by others 965,613 — —	Investments:						
Fixed income securities: U.S. government securities 423,138 — Domestic bonds and long term notes 622,857 194,229 428,605 23 International bonds and long term notes 622,857 194,229 428,605 23 U.S. equity securities 633,548 274,633 80,01-U.S. equity securities 633,548 274,633 818,885 3 Non-U.S. equity securities 633,548 274,633 358,915 — Natural resources 317,874 Private market investments 1,127,163 Hedged strategies 891,345 — 1,127,163 Hedged strategies 891,345 — 219,328 672,017 Real estate investments 266,451 59,240 4,233 202,978 Miscellaneous investments 3,026 3,026 — — Total investments Total investments 1,127,163 Interest in perpetual funds held by others 965,613 — 965,613 — 965,613 Total assets Financial liabilities: Derivative instruments interest rate swaps Derivative instruments futures contracts futures contracts futures contracts (1,079) — (140,173) — Deposits held in custody for others (465,776) — (465,776) — (465,776) — 194,239 428,605 23 428,605 23 428,605 23 428,605 23 428,605 23 428,605 23 428,605 23 428,605 23 428,605 23 428,605 23 428,605 23 428,605 24 428,605	Short-term investments and						
U.S. government securities 423,138 — 423,138 — Domestic bonds and long term notes 622,857 194,229 428,605 23 International bonds and long term notes 221,724 — 221,724 — U.S. equity securities 633,548 274,633 358,915 — Natural resources 317,874 — — 317,874 Private market investments 1,127,163 — — 1,127,163 Hedged strategies 891,345 — 219,328 672,017 Real estate investments 266,451 59,240 4,233 202,978 Miscellaneous investments 3,026 3,026 — — — Total investments 3,026 3,026 — — — Total investments 965,613 — — 965,613 Total assets (1) \$ 6,365,431 1,141,526 1,938,234 3,285,671 Financial liabilities: Derivative instruments interest rate swaps 1,140,173 — (140,173) — 1,140,173 — 1,140,173 — 1,140,173 — 1,140,173 — 1,140,173 — 1,140,173 — 1,140,174 — 1,140	cash equivalents	\$	228,763	228,357	406	_	
Securities	Fixed income securities:						
Domestic bonds and long term notes 622,857 194,229 428,605 23	U.S. government						
long term notes	securities		423,138	_	423,138	_	
International bonds and long term notes	Domestic bonds and						
Long term notes 221,724	long term notes		622,857	194,229	428,605	23	
U.S. equity securities 663,929 382,041 281,885 3 Non-U.S. equity securities 633,548 274,633 358,915 — Natural resources 317,874 — — 317,874 Private market investments 1,127,163 — — 1,127,163 Hedged strategies 891,345 — 219,328 672,017 Real estate investments 266,451 59,240 4,233 202,978 Miscellaneous investments 3,026 3,026 — — Total investments (1) 5,399,818 1,141,526 1,938,234 2,320,058 Interest in perpetual funds held by others 965,613 — — 965,613 Total assets (1) \$ 6,365,431 1,141,526 1,938,234 3,285,671 Financial liabilities: Derivative instruments - interest rate swaps (140,173) — (140,173) — Derivative instruments - futures contracts (1,079) — (1,079) — Deposits held in custody for others (465,	International bonds and						
Non-U.S. equity securities	long term notes		221,724	_	221,724	_	
Natural resources 317,874 — — 317,874 Private market investments 1,127,163 — — 1,127,163 Hedged strategies 891,345 — 219,328 672,017 Real estate investments 266,451 59,240 4,233 202,978 Miscellaneous investments 3,026 3,026 — — Total investments 5,399,818 1,141,526 1,938,234 2,320,058 Interest in perpetual funds held by others 965,613 — — 965,613 Total assets (1) \$ 6,365,431 1,141,526 1,938,234 3,285,671 Financial liabilities: Derivative instruments - interest rate swaps (140,173) — (140,173) — Derivative instruments - futures contracts (1,079) — (1,079) — Deposits held in custody for others (465,776) — (465,776) — —	U.S. equity securities		663,929	382,041	281,885	3	
Private market investments 1,127,163 — — 1,127,163 Hedged strategies 891,345 — 219,328 672,017 Real estate investments 266,451 59,240 4,233 202,978 Miscellaneous investments 3,026 3,026 — — Total investments (1) 5,399,818 1,141,526 1,938,234 2,320,058 Interest in perpetual funds held by others 965,613 — — 965,613 Total assets (1) \$ 6,365,431 1,141,526 1,938,234 3,285,671 Financial liabilities: Derivative instruments - interest rate swaps (140,173) — (140,173) — Derivative instruments - futures contracts (1,079) — (1,079) — Deposits held in custody for others (465,776) — (465,776) —	Non-U.S. equity securities		633,548	274,633	358,915	_	
Hedged strategies	Natural resources		317,874	_	_	317,874	
Real estate investments 266,451 59,240 4,233 202,978 Miscellaneous investments 3,026 3,026 — — Total investments (1) 5,399,818 1,141,526 1,938,234 2,320,058 Interest in perpetual funds held by others 965,613 — — 965,613 Total assets (1) \$ 6,365,431 1,141,526 1,938,234 3,285,671 Financial liabilities: Derivative instruments - interest rate swaps (140,173) — (140,173) — Derivative instruments - futures contracts (1,079) — (1,079) — Deposits held in custody for others (465,776) — (465,776) —	Private market investments		1,127,163	_	_	1,127,163	
Miscellaneous investments 3,026 3,026 - - - Total investments (1) 5,399,818 1,141,526 1,938,234 2,320,058 Interest in perpetual funds held by others 965,613 - - 965,613 Total assets (1) \$ 6,365,431 1,141,526 1,938,234 3,285,671 Financial liabilities: Derivative instruments -	Hedged strategies		891,345	_	219,328	672,017	
Total investments (1)	Real estate investments		266,451	59,240	4,233	202,978	
Interest in perpetual funds held by others 965,613 — 965,613 Total assets (1) \$ 6,365,431	Miscellaneous investments	_	3,026	3,026			
Interest in perpetual funds held by others 965,613 — 965,613 Total assets (1) \$ 6,365,431	Total investments (1)		5,399,818	1,141,526	1,938,234	2,320,058	
by others 965,613 — — 965,613 Total assets (1) \$ 6,365,431							
Financial liabilities: Derivative instruments - interest rate swaps Derivative instruments - futures contracts Deposits held in custody for others (140,173)			965,613			965,613	
Derivative instruments - (140,173) — (140,173) — Derivative instruments - (1,079) — (1,079) — futures contracts (1,079) — (1,079) — Deposits held in custody for others (465,776) — (465,776) —	Total assets (1)	\$_	6,365,431	1,141,526	1,938,234	3,285,671	
Derivative instruments - (140,173) — (140,173) — Derivative instruments - (1,079) — (1,079) — futures contracts (1,079) — (1,079) — Deposits held in custody for others (465,776) — (465,776) —	Financial liabilities:						
Derivative instruments - futures contracts (1,079) — (1,079) — Deposits held in custody for others (465,776) — (465,776) —							
Derivative instruments - futures contracts (1,079) — (1,079) — Deposits held in custody for others (465,776) — (465,776) —	interest rate swaps		(140,173)	_	(140,173)	_	
futures contracts (1,079) — (1,079) — Deposits held in custody for others (465,776) — (465,776) —	<u>*</u>		(-13,-12)		(,)		
Deposits held in custody for others (465,776) — (465,776) —			(1.079)	_	(1.079)	_	
for others (465,776) — (465,776) —	Deposits held in custody		(,= ,		(, , , , ,		
Total liabilities \$ (607,028) — (607,028) —	÷ • • • • • • • • • • • • • • • • • • •		(465,776)		(465,776)		
	Total liabilities	\$	(607,028)	_	(607,028)	_	

⁽¹⁾ Certain investments in joint ventures carried under the equity method of accounting are not reported at fair value and thus not included in the table above.

The University has \$5.57 billion and \$5.22 billion of investments and investments in perpetual funds held by others that fall into Levels 2 and 3 and are reported at estimated fair value at August 31, 2012 and 2011, respectively. Unless it is probable that all or a portion of the investment will be sold for an amount

Notes to Consolidated Financial Statements
August 31, 2012 and 2011

different from net asset value, the University has applied a practical expedient and concluded that the net asset value reported by the underlying fund approximates the fair value of these investments.

While the University's investment in these funds is classified as Level 2 or 3, the underlying investments of the fund may be classified Level 1 by the fund itself. The categorization of an investment within the hierarchy does not necessarily correspond to the perceived risk of that investment. The funds and the University use inputs in applying various valuation techniques that are assumptions which market participants use to make valuation decisions, including assumptions about risk. Inputs may include price information, volatility statistics, operating statistics, specific and broad credit data, liquidity statistics, recent transactions, earnings forecasts, future cash flows, market multiples, discount rates and other factors.

Investments made directly by the University whose values are based on quoted market prices in active markets, and are therefore classified within Level 1, include actively traded common and preferred stock, U.S. government fixed income instruments and non-U.S. government fixed income instruments. Level 1 investments may also include futures contracts, listed mutual funds, exchange traded funds (ETFs) and money market funds.

Investments that trade in markets that are considered to be active, but are based on dealer quotations or alternative pricing sources supported by observable inputs or investments that trade in markets that are not considered to be active, but are valued based on quoted market prices, dealer quotations or alternative pricing sources supported by observable inputs are classified within Level 2. Alternative pricing sources include quotations from market participants and pricing models which are based on accepted industry modeling techniques. These investments include U.S. investment-grade and below investment-grade debt securities, international corporate bonds, mortgage-backed securities, asset-backed securities, senior loans and bank loans, most derivative contracts other than futures, and commingled fund investments that would otherwise be classified Level 3 but for which the University had the ability to redeem at net asset value on or within 120 days after August 31, 2012 and 2011.

Investments classified within Level 3 have significant unobservable inputs, as they trade infrequently or not at all. Level 3 investments include limited partnerships, private placement investments, and commingled fund investments. Inputs used may include the original transaction price, recent transactions in the same or similar market, completed or pending third-party transactions in the underlying investment or comparable issuers, and subsequent rounds of financing. When observable prices are not available these investments are valued using one or more valuation techniques described below.

- Market Approach: This approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities.
- Income Approach: This approach determines a valuation by discounting future cash flows.
- Cost Approach: This approach is based on the principle of substitution and the concept that a market participant would not pay more than the amount that would currently be required to replace the asset. Although a secondary market exists for these investments, it is not active and individual transactions are typically not observable. When transactions do occur in this limited secondary market, they may occur at discounts to the reported net asset value.

Notes to Consolidated Financial Statements August 31, 2012 and 2011

The following tables summarize the University's Level 3 reconciliation as of August 31, 2012 and 2011 (in thousands):

	_	Balance as of August 31, 2011	Net realized and unrealized gains (losses)	Purchases	Sales	Transfer in (out) Level 3	Balance as of August 31, 2012
Investments:							
Fixed income securities	\$	23	24	_	(12)	_	35
U.S. equity securities		3	_	_	_	_	3
Natural resources		317,874	54,917	44,656	(18,829)	_	398,618
Private market investments		1,127,163	14,038	316,846	(253,298)	_	1,204,749
Hedged strategies		672,017	41,789	307,973	(193,556)	(53,947)	774,276
Real estate investments	_	202,978	(3,495)	31,246	(27,462)		203,267
Total investments Interest in perpetual funds		2,320,058	107,273	700,721	(493,157)	(53,947)	2,580,948
held by others	_	965,613	54,433			5,802	1,025,848
Total assets	\$	3,285,671	161,706	700,721	(493,157)	(48,145)	3,606,796

Of the \$107.3 million in Level 3 Net Realized and Unrealized Gains for investments for the year ended August 31, 2012, approximately \$95.3 million is the unrealized gain associated with investments held by the University for the entire year. The transfers from Level 3 into Level 2 are comprised of \$53.9 million in liquidity restriction changes.

	_	Balance as of August 31, 2010	Net realized and unrealized gains (losses)	Purchases	Sales	Transfer into Level 3	Balance as of August 31, 2011
Investments:							
Fixed income securities	\$	1,723	307	_	(2,007)	_	23
U.S. equity securities		3	_	_	_	_	3
Natural resources		277,695	21,066	39,928	(20,815)	_	317,874
Private market investments		1,009,759	54,695	188,811	(126,102)	_	1,127,163
Hedged strategies		625,952	54,072	127,491	(135,864)	366	672,017
Real estate investments	_	195,554	(3,331)	24,672	(13,917)		202,978
Total investments		2,110,686	126,809	380,902	(298,705)	366	2,320,058
Interest in perpetual funds							
held by others	_	781,192	184,421				965,613
Total assets	\$_	2,891,878	311,230	380,902	(298,705)	366	3,285,671

Of the \$126.8 million in Level 3 Net Realized and Unrealized Gains for investments for the year ended August 31, 2011, approximately \$130.0 million is the unrealized gain associated with investments held by the University for the entire year. The transfers from Level 2 into Level 3 are comprised of \$0.4 million in liquidity restriction changes.

Notes to Consolidated Financial Statements
August 31, 2012 and 2011

(10) Property and Equipment

Property and equipment at August 31 are summarized as follows (in thousands):

		2012	2011
Land and land improvements	\$	173,460	154,736
Buildings and improvements		2,666,455	2,413,857
Equipment		1,760,920	1,457,823
Library and museum assets		313,858	296,568
Construction in progress	_	162,413	68,762
		5,077,106	4,391,746
Less accumulated depreciation	_	(2,413,664)	(1,963,520)
	\$ _	2,663,442	2,428,226

Property and equipment is reviewed for recoverability whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss shall be recognized only if the carrying amount of a long-lived asset is not recoverable and exceeds its fair value. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. During 2012, plans to demolish buildings located on property owned by Emory were finalized, resulting in an impairment loss of \$8.2 million.

The University has identified asset retirement obligations primarily from commitments to remove asbestos and lead paint in University facilities at the time of major renovation or demolition. The liability was estimated using an inflation rate of 5.00% and discount rate of 4.74%. The liability for asset retirement obligations at August 31, 2012 and 2011 is \$50.7 million and \$49.7 million, respectively, and is included in accounts payable and accrued liabilities in the accompanying consolidated financial statements.

Notes to Consolidated Financial Statements August 31, 2012 and 2011

(11) Long-Term Debt

Bonds, notes and mortgages payable, including unamortized premiums and discounts, consisted of the following at August 31 (dollars in thousands):

	Interest rate	Final Outstanding		principal	
	average	maturity	2012	2011	
Tax-exempt fixed-rate revenue bonds:					
2011 Series A (1)	4.95%	September 1, 2041 \$	236,980	238,278	
2009 Series B (2)	4.73	September 1, 2035	231,308	238,329	
2009 Series C	4.90	September 1, 2039	99,558	99,633	
2008 Series C	4.96	September 1, 2038	124,231	124,299	
2005 Series A	4.84	September 1, 2025	117,536	130,482	
2002 Series A	4.67	September 1, 2033	49,068	55,305	
2001 Series A		September 1, 2025		4,220	
1998 Series B	5.00	November 1, 2033	7,767	7,757	
Total tax-exempt fixed-rate r	evenue bonds	_	866,448	898,303	
Tax-exempt variable-rate revenue bonds:					
2007 Series A (3)	1.13	November 15, 2028	11,090	_	
2005 Series B	0.11	September 1, 2035	250,000	250,000	
2005 Series C	0.11	September 1, 2036	281,575	281,575	
Total tax-exempt variable-rat	te revenue bonds	_	542,665	531,575	
Taxable fixed-rate revenue bonds:					
2009 Series A	5.63	September 1, 2019	249,016	248,875	
1994 Series C	8.00	October 1, 2024	6,945	7,240	
Series 1991	8.90	April 1, 2022	2,231	2,616	
Total taxable fixed-rate rever	nue bonds	_	258,192	258,731	
Taxable variable-rate revenue bonds:					
1999 Series B	0.22	November 1, 2029	11,085	11,415	
1995 Series B	0.22	November 1, 2025	8,875	10,455	
1994 Series B	0.16	October 1, 2024	11,100	11,605	
Total taxable variable-rate re	venue bonds	_	31,060	33,475	
Commercial paper:					
2010 Program 1 - Tax-exempt	0.13	August 1, 2050	19,930	25,950	
2008 Program 1 - Taxable	0.19	April 1, 2047	100,000	38,000	
Total commercial paper		_	119,930	63,950	
Other variable rate notes and mortgages	Various		2,288	2,397	
Line of credit			70,150		
Total bonds, notes and mortg	rages navahle	- \$	1,890,733	1,788,431	
rotal bolids, notes and mortg	ages payable	^ф =	1,070,733	1,700,431	

Notes to Consolidated Financial Statements August 31, 2012 and 2011

- (1) Included in the 2011 Series Bonds is a 5 year maturity of \$92.2 million due on September 1, 2016 at an average interest rate of 4.88%.
- (2) Included in the 2009 Series Bonds is a medium-term maturity of \$43.0 million due on September 1, 2019 at an average interest rate of 4.68%.
- (3) Interest rate reflected in the chart is calculated for the period that the University owned SJHA during fiscal 2012.

The University incurred interest expense of \$74.8 million and \$75.5 million in 2012 and 2011, respectively, net of capitalized interest of \$2.0 million and \$1.0 million in 2012 and 2011, respectively. During 2012, the average interest rate on University tax-exempt variable rate demand bonds (VRDB) and taxable debt was 0.11% and 0.19%, respectively. Related indices for this period were 0.15% for tax-exempt debt (The Securities Industry and Financial Markets Association Index – SIFMA) and 0.25% for taxable debt (London Interbank Offered Rate – LIBOR).

At August 31, 2012 the aggregate annual maturities of bonds, notes and mortgages payable for the next five years and thereafter are as follows (in thousands):

Payable in fiscal year:	
2013	\$ 48,675
2014	28,795
2015	33,305
2016	30,675
2017	113,698
Thereafter	1,596,656
	1,851,804
Unamortized net premium	38,929
	\$ 1,890,733

On August 18, 2010, the University established a \$400 million tax-exempt Commercial Paper program. The primary purpose of the program is to meet interim financing needs related to capital projects. As of August 31, 2012 and 2011, the University had outstanding balances of \$19.9 million and \$26.0 million, respectively, under this program. On September 4, 2012 the University issued an additional \$28 million to refund \$28.0 million of the Series 2002A Bonds.

In 2008, the University established a \$100 million taxable Commercial Paper program. As of August 31, 2011, the University had an outstanding balance of \$38 million. On June 28, 2012, the University issued an additional \$62 million of the taxable Commercial Paper to refund 2009 Series debt, which resulted in an outstanding balance of \$100 million in taxable Commercial Paper as of August 31, 2012.

The University has standby credit facilities to enable the University to purchase tendered variable rate debt in the event of a failed remarketing. Currently, it has two diversified facilities totaling \$290 million that are committed for this sole purpose and cannot be used for operating needs of the University. As of August 31, 2012, there were no draws against these lines of credit.

Notes to Consolidated Financial Statements
August 31, 2012 and 2011

The University also has a \$100 million line of credit and Emory Clinic has a \$15 million line of credit at August 31, 2012. During fiscal 2012, \$70 million was drawn against the University line of credit to refund portions of the outstanding 2009 and 2010 debt series. There have been no draws on the Clinic line of credit.

Emory University has two letters of credit with a commercial bank totaling \$2.1 million. There were no draws against these letters of credit as of August 31, 2012 and 2011.

In conjunction with Emory Healthcare's 35% joint venture interest in Emory-Adventist, Inc. the University has guaranteed \$7.3 million of a \$20.8 million outstanding loan payable to Adventist Health System.

The terms of the University's long-term debt provide for certain financial and nonfinancial covenants, including provisions as to the use of the proceeds, limits as to arbitrage and bond issue costs, and various other administrative requirements. At August 31, 2012, management believes that the University was in compliance with these covenants.

With regard to debt funding and in response to significant and recent economic changes altering the credit risk environment, the primary objectives of Emory's debt policy are to optimize its current and expected future debt structure and to maintain a diversified portfolio of debt within acceptable risk tolerances while decreasing the cost of capital. The policy is designed to manage the acquisition and allocation of debt as an important component of Emory's overall capital structure.

2012

2011

(12) Temporarily and Permanently Restricted Net Assets

Temporarily restricted net assets consist of the following as of August 31 (in thousands):

	 2012	2011
Appreciation on endowments restricted until appropriated	\$ 2,060,189	1,994,079
Term endowments	120,118	120,063
Contributions receivable, time and purpose restricted	133,874	152,870
Capital projects and other donor designations	202,162	108,777
Annuity and life income agreements	 8,572	7,599
	\$ 2,524,915	2,383,388

Notes to Consolidated Financial Statements August 31, 2012 and 2011

Permanently restricted net assets include endowment funds subject to UPMIFA (note 7) as well as perpetual trusts and endowments held by others. Investments to be held in perpetuity reflect a reduction for contributions not yet received. Permanently restricted net assets as of August 31 are comprised of (in thousands):

	_	2012	2011
Investments to be held in perpetuity, the income	Φ.	1.504.054	1 450 000
from which is expendable for operating activities	\$	1,534,074	1,459,830
Contributions receivable, restricted for endowment		22,773	22,299
Endowments requiring income to be added to the			
original gift until funds reach a stipulated balance		13,372	12,761
Annuity and life income agreements		2,021	1,906
	\$	1,572,240	1,496,796

Generally, the donors of these restricted gifts permit the University to use all or part of the income earned and net appreciation on related investments for general or specific purposes, such as scholarships, faculty salaries or other operational and administrative support.

(13) Investment Return

Investment returns, as reflected in the accompanying consolidated statements of activities, for August 31 are as follows (in thousands):

	 2012	2011
Endowment spending distribution Other investment income designated for current operations	\$ 176,541 56,437	169,533 35,639
Total operating return	232,978	205,172
Unrealized gains on investments, net Investment income and net realized gains less	108,775	270,769
spending distribution for current operations	194,500	338,221
Total nonoperating gain	 303,275	608,990
Total investment return	\$ 536,253	814,162

The components of investment return for August 31 are reflected below (in thousands):

	 2012	2011
Investment income	\$ 133,811	134,361
Realized gains on investments	293,667	409,032
Unrealized gains on investments, net	 108,775	270,769
Total investment return	\$ 536,253	814,162

Notes to Consolidated Financial Statements
August 31, 2012 and 2011

In addition to a core group of investment professionals dedicated to the management of Emory's endowment, the University also employs external investment managers. External management fees paid directly (i.e., segregated investment account fees, custody fees, and consulting reviews) totaled \$12.5 million and \$18.0 million, and internal management fees (including staff expenses) totaled \$6.6 million and \$5.9 million in fiscal 2012 and 2011, respectively.

(14) Contributory Retirement Plans

The University has a contributory retirement plan covering certain employees and teaching staff. The University contributes an amount equal to 6% of each eligible employee's compensation to the plan as well as a supplemental contribution of 3% based on a 1.5-to-1 match of employee contributions of up to 2% of compensation. Emory Healthcare sponsors a retirement plan, covering most full-time employees, under which annuities are purchased with contributions by Emory Healthcare and its employees. The benefits are vested only to the extent of the annuities purchased. In fiscal 2012, Emory Healthcare increased the benefits provided to employees in connection with the curtailment of the pension plan. The Emory Clinic (TEC) sponsors The Emory Clinic, Inc. Retirement Savings Plan (the Plan), covering all its employees, except those considered leased employees or those covered under collective bargaining agreements, as defined. The Plan provides for employees to make salary reduction contributions and for TEC to make discretionary contributions to employees who have attained the age of 21 and are employees at the date the contribution is made. The Plan provides for contributions at an annual determined percentage of compensation and employees cliff vest in employer contributions after five years of service. Retirement expense totaled \$99.8 million and \$79.2 million during 2012 and 2011, respectively, and is included in operating expense in the accompanying consolidated statements of activities.

(15) Pension Plan

Emory Healthcare sponsors a defined benefit pension plan (the Plan) covering all employees who have attained the age of 21 and completed one year of service as defined in the Plan. Emory Healthcare contributes an amount sufficient to fund the Plan as determined by consulting actuaries. Plan assets generally consist of equity and fixed income securities. Emory Healthcare measures its participation in the Plan at August 31.

On May 25, 2011, the System's board approved the curtailment of the Plan, effective December 31, 2011. The terms of the curtailment generally provide that no further benefit accrual under the Plan is provided for service after the effective date nor will new entrants into the Plan be permitted after the effective date. The financial impact of the curtailment was recognized in the System's fiscal 2011 combined financial statements in net periodic pension cost. A discount rate of 5.84% was used to measure obligations at the curtailment date.

Notes to Consolidated Financial Statements August 31, 2012 and 2011

The changes in the projected benefit obligation as of August 31 follow (in thousands):

	 2012	2011
Projected benefit obligation, beginning of year	\$ 189,120	186,054
Service cost - curtailed	8,255	24,274
Interest cost	10,596	10,077
Actuarial loss (gain)	48,353	(29,069)
Benefits paid	 (2,811)	(2,216)
Projected benefit obligation, end of year	\$ 253,513	189,120

Given the fiscal 2011 decision to curtail the plan, the accumulated benefit obligation is the same as the projected benefit obligation, for both years.

The changes in the fair value of plan assets, funded status of the plan, and the status of amounts recognized in the accompanying consolidated statements of financial position as of August 31 follow (in thousands):

	2012	2011
Fair value of plan assets, beginning of year Actual return on plan assets Employer contributions Benefits paid	\$ 146,346 18,754 8,900 (2,811)	106,458 13,819 28,285 (2,216)
Fair value of plan assets, end of year	\$ 171,189	146,346
Funded status (deficit) Accrued pension cost recognized in the	\$ (82,324)	(42,774)
consolidated statements of financial position	\$ (82,324)	(42,774)

The components of net periodic pension cost for 2012 and 2011 follow (in thousands):

	 2012	2011
Service cost	\$ 8,255	24,274
Interest cost	10,596	10,077
Expected return on plan assets	(12,846)	(11,012)
Amortization of prior service cost		404
Recognized actuarial loss	1,508	3,536
Curtailment loss	 <u> </u>	1,008
	\$ 7,513	28,287

The amounts accumulated in unrestricted net assets for net unrecognized actuarial loss totaled \$81.4 million and \$40.4 million in fiscal 2012 and 2011, respectively.

Notes to Consolidated Financial Statements August 31, 2012 and 2011

A net loss of \$6.7 million is expected to be amortized from unrestricted net assets into net periodic pension cost in fiscal 2013.

Weighted average assumptions used to determine benefit obligations in the accompanying consolidated statements of financial position for 2012 and 2011 follow:

	2012	2011
Discount rate	4.41%	5.64%
Expected long-term rate of return on plan assets	8.00	8.00
Rate of compensation increase	n/a	3.50

Weighted average assumptions used to determine net periodic pension cost for 2012 and 2011 follow:

	2012	2011
Discount rate	5.64%	5.42%
Expected return on plan assets	8.00	8.00
Rate of compensation increase	n/a	3.50

Plan Assets

The Plan's investment objectives are to protect long-term asset value by applying prudent, low-risk, high-quality investment disciplines and to enhance the values by maximizing investment returns through active security management within the framework of the Plan's investment policy. Asset allocation strategies and investment management structure are designed to meet the Plan's investment objectives.

The Plan's expected long-term rate of return on assets is determined by reviewing the historical return of each asset category comprising the Plan's target asset allocation. This review produces an annual return assumption for each asset category. The product of the annual return assumption and the Plan's target asset allocation percentage for each asset category equals the annual return attribution by asset category.

The following table summarizes the Plan's assets which are recorded at fair value as of August 31 (in thousands):

	2012						
	_	Total	Fai	r value hierarc	hy	Target	Total asset
		fair value	Level 1	Level 2	Level 3	allocation	allocation
Financial assets:	_						
Investments:							
Short-term investments and	d						
cash equivalents	\$	61	61	_	_	%	%
U.S. equity securities		60,550		60,550		55	35
Debt securities		55,952	_	55,952	_	30	33
International equities	_	54,626		54,626		15	32
Total assets	\$_	171,189	61	171,128		100%	100%

Notes to Consolidated Financial Statements

August 31, 2012 and 2011

		2011						
		Total	Fai	r value hierarc	hy	Target	Total asset	
		fair value	Level 1	Level 2	Level 3	allocation	allocation	
Financial assets:	_							
Investments:								
Short-term investments an	nd							
cash equivalents	\$	41	41			%	%	
U.S. equity securities		77,458		77,458		55	53	
Debt securities		47,886		47,886		30	33	
International equities	_	20,961		20,961		15	14	
Total assets	\$_	146,346	41	146,305		100%	100%	

2011

Cash Flows

Emory Healthcare does not expect to contribute to the Plan in fiscal 2013.

Expected Future Benefit Payments

Annual future benefit payments, excluding lump sum settlements, are expected to range from \$3.0 million to \$10.0 million, for the next five years.

Other Items

Emory Healthcare uses the straight-line method to amortize prior service cost.

(16) Pension Plan – JOC

In connection with the formation of the JOC, the JOC assumed certain defined benefit pension liabilities covering certain employees of the contributed entities. Prior to formation of the JOC, the Plan was curtailed so that generally no further benefit accrual is provided for service after December 31, 2011. In addition, the JOC has agreed to provide for funding of the plan generally over the next 10 years, beginning in fiscal 2015, subject to certain terms and conditions.

At the time of the formation of the JOC and assumption of control over the JOC by the System, the System recognized as part of the business combination a liability representing the unfunded status of the SJHS Pension Plan, in accordance with FASB ASC 805-20, *Business Combinations – Identifiable Assets, Liabilities, and Any Noncontrolling Interest.* The SJHS Pension Plan is accounted for by the System as a multiple-employer plan in accordance with FASB ASC 715-30, *Defined Benefit Plans – Pension*.

Notes to Consolidated Financial Statements August 31, 2012 and 2011

The changes in the projected benefit obligation as of August 31 follow (in thousands):

	 2012
Projected benefit obligation, December 31	\$ 121,654
Service cost	_
Interest cost	3,480
Actuarial loss	10,902
Benefits paid	 (1,895)
Projected benefit obligation, end of year	\$ 134,141

Given the curtailment of the plan prior to the formation of the JOC, the accumulated benefit obligation at August 31, 2012 is the same as the projected benefit obligation.

The changes in fair value of plan assets, funded status of the plan, and the status of amounts recognized in Emory's accompanying consolidated statement of financial position as of August 31 follow (in thousands):

	 2012
Fair value of plan assets, December 31 Actual return on plan assets Benefits paid	\$ 74,274 5,951 (1,895)
Fair value of plan assets, end of year	\$ 78,330
Funded status (deficit)	(55,811)
Accrued pension cost	\$ (55,811)

The components of net periodic pension cost follow (in thousands):

	2012
Service cost	\$ _
Interest cost	3,480
Expected return on plan assets	(3,633)
Amortization of prior service cost	(292)
Recognized actuarial loss	 863
Net periodic pension cost	\$ 418

Notes to Consolidated Financial Statements August 31, 2012 and 2011

The amounts accumulated in unrestricted net assets follow (in thousands):

	2012
Prior service cost Net loss	\$ (15,312) 72,011
Net loss	72,011
	\$ 56,699

A net loss of \$940 is expected to be amortized from unrestricted net assets into net periodic pension cost in fiscal 2013.

Weighted average assumptions used to determine benefit obligations in the accompanying consolidated statement of financial position for 2012 follow:

	2012
Discount rate	3.55%
Expected long-term rate of return on plan assets	7.50
Rate of compensation increase	n/a

Weighted average assumptions used to determine net periodic pension cost for 2012 follow:

	2012
Discount rate	4.35%
Expected return on plan assets	7.50
Rate of compensation increase	n/a

Plan Assets

Under the terms of the agreement forming the JOC, the assets of the SJHS Pension Plan formally remain assets of SJHS and the plan assets remain invested in the CHE Pension Investment Program. Accordingly, neither the JOC nor the System has discretion over the management of the plan assets. However, the plan assets related to the entities contributed to the JOC (and certain other employees leased to the JOC) are contractually required to be clearly separated from the plan assets of the other entities participating in the Catholic Health East Employee Pension Program. The SJHS Pension Plan's investment objectives are to protect long-term asset value by applying prudent, low-risk, high-quality investment disciplines and to enhance the values by maximizing investment returns through active security management within the framework of the plan's investment policy. Asset allocation strategies and investment management structure are designed to meet the plan's investment objectives.

The SJHS Pension Plan's expected long-term rate of return on assets is determined by reviewing the historical return of each asset category comprising the plan's target asset allocation. This review produces an annual return assumption for each asset category. The product of the annual return assumption and the SJHS Pension Plan's target asset allocation percentage for each asset category equals the annual return attribution by asset category.

Notes to Consolidated Financial Statements August 31, 2012 and 2011

The following table summarizes the Plan's assets which are recorded at fair value as of August 31, 2012 (in thousands):

		2012					
	-	Total	Fai	Target	Total asset		
		fair value	Level 1	Level 2	Level 3	allocation	allocation
Financial assets:	-			<u> </u>			
Investments:							
Short-term investments an	d						
cash equivalents	\$	4,219	4,219	_	_	5%	5%
U.S. equity securities		48,429	22,055	26,374	_	58	62
Debt securities		10,138	10,138	_	_	14	13
International equities		7,499	3,707	3,792	_	11	10
Managed funds	_	8,045			8,045	12	10
Total assets	\$	78,330	40,119	30,166	8,045	100%	100%

Cash Flows

The System does not expect to contribute to the SJHS Pension Plan in fiscal 2013.

Expected Future Benefit Payments

Annual future benefit payments, excluding lump sum settlements, are expected to range from \$3.0 million to \$6.0 million, for the next five years.

Other Items

The System uses the straight-line method to amortize prior service cost.

(17) Postretirement Healthcare and Life Insurance Benefits

Effective January 1, 2003, the University discontinued subsidizing retiree healthcare and life insurance benefits for new employees. All University employees hired prior to January 1, 2003 and certain employees of Emory Healthcare who meet age and service requirements continue to be eligible for the retiree benefits. The cost of providing these benefits is shared with retirees. Emory University has reserved the right to make further changes or terminate these benefit plans.

The University and Emory Healthcare each fund a separate trust (VEBA Trust) for these retiree health and life benefits. The assets of the VEBA Trust are invested primarily in equity and fixed income securities. The University funds these benefits only to the extent of current retiree claims. The University measures its participation in the VEBA Trust at August 31.

Notes to Consolidated Financial Statements August 31, 2012 and 2011

The changes in the accumulated postretirement benefit obligation (APBO) as of August 31 are as follows (in thousands):

			2012		2011
	_	Emory University	Emory Healthcare	Total	Total
APBO, beginning of year	\$	66,886	37,289	104,175	102,322
Service cost		1,447	743	2,190	2,401
Interest cost		3,721	2,079	5,800	5,473
Actuarial loss		9,058	5,001	14,059	(1,857)
Benefits paid		(3,608)	(1,433)	(5,041)	(4,813)
Retiree drug subsidy paid	_	510	219	729	649
APBO, end of year	\$_	78,014	43,898	121,912	104,175

The changes in the fair value of plan assets, funded status of the plan and the status of the accrued postretirement benefit obligation recognized in the accompanying consolidated statements of financial position as of August 31 are as follows (in thousands):

			2011		
	_	Emory University	Emory Healthcare	Total	Total
Fair value of plan assets,	-	<u> </u>			_
beginning of year	\$	42,513	17,825	60,338	58,853
Actual return on plan assets		3,376	1,556	4,932	6,272
Benefits paid by Emory		(2,920)	(1,433)	(4,353)	(5,436)
Retiree drug subsidy	_	510	219	729	649
Fair value of plan assets,					
end of year	\$ _	43,479	18,167	61,646	60,338
Funded status (deficit)	\$_	(34,535)	(25,731)	(60,266)	(43,837)
Accrued postretirement benefit cost recognized in the consolidated					
statements of financial position	\$_	(34,535)	(25,731)	(60,266)	(43,837)

Actuarial assumptions used to determine the values of the APBO at August 31, 2012 and 2011 and the benefit costs for years ended August 31, 2012 and 2011 included a discount rate of 4.41% and 5.64%, respectively. Since the plan was amended on April 11, 2002 to limit the University's liability for future medical care cost increases to 4.00%, the per capita cost increase of healthcare benefits is capped at 4.00%

Notes to Consolidated Financial Statements August 31, 2012 and 2011

beginning with fiscal 2002. The estimated long-term rate of return on plan assets was 8.00% for the University and Emory Healthcare for both years ended August 31, 2012 and 2011. A graded plan participation for election of medical coverage upon retirement has been assumed. This payment schedule reflects the new plan design which will accelerate the increase in retiree contributions, which is expected to result in more retirees electing not to continue coverage under the University's plan. All University retirees are assumed to elect life insurance benefits, regardless of their medical plan election.

The components of net periodic postretirement benefit cost for years ended August 31 were as follows (in thousands):

		2012			2011
	_	Emory University	Emory Healthcare	Total	Total
Service cost of benefits earned	\$	1,447	743	2,190	2,401
Interest cost on APBO		3,721	2,079	5,800	5,473
Expected return on plan assets		(3,257)	(1,364)	(4,621)	(4,516)
Amortization of prior service cost		_	_	_	(1,537)
Recognized net actuarial loss	_	2,387	1,696	4,083	4,660
Net periodic postretirement					
benefit cost	\$_	4,298	3,154	7,452	6,481

The amounts accumulated in unrestricted net assets follow (in thousands):

		2012	2011	
	Emo Unive	v	•	Total
Net unrecognized actuarial loss	<u>4</u>	4,083 24,	625 68,708	58,916

In fiscal 2013, net unrecognized actuarial losses of \$2.8 million for Emory University and \$2.0 million for Emory Healthcare are expected to be amortized from unrestricted net assets into net periodic postretirement benefit credit.

Plan Assets

The Investment Committee of the Emory University Board of Trustees approves the investment guidelines and asset allocation targets for the pension benefits and postretirement benefits plans. The primary objective of the investments is to ensure the solvency of the plans over time to meet plan obligations. The secondary objective is to meet or exceed the plans' actuarial assumed rate of return over time, without taking excess risk. The funds are diversified by asset class in accordance with established allocation targets and rebalanced as needed. Specific investments are apportioned to a combination of institutional pooled funds and mutual funds.

Notes to Consolidated Financial Statements August 31, 2012 and 2011

The following tables summarize the University's VEBA Trust assets as of August 31 (in thousands):

				201	2		
	_	Total	Fair	r value hierarch	ny	Target	Total asset
		fair value	Level 1	Level 2	Level 3	allocation	allocation
Financial assets:							
Investments:							
Short-term investments and	l						
cash equivalents	\$	12	12	_		%	%
U.S. equity securities		17,482	12,250	5,232		40	40
Debt securities		10,668	7,872	2,796		25	25
International equities	_	15,317		15,317		35	35
Total assets	\$	43,479	20,134	23,345		100%	100%
				201	11		
		Total	Fai	ir value hierarc		Target	Total asset
		fair value	Level 1	Level 2	Level 3	allocation	allocation
Financial assets:							
Investments:							
Short-term investments and	l						
cash equivalents	\$	1	1	_		%	%
U.S. equity securities		16,473	10,781	5,692		40	39
Debt securities		11,531	7,850	3,681		35	27
International equities		14,508		14,508		25	34
Total assets	\$	42,513	18,632	23,881		100%	100%

Notes to Consolidated Financial Statements August 31, 2012 and 2011

The following tables summarize Emory Healthcare's VEBA Trust assets as of August 31 (in thousands):

2012

	Total	Fair value hierarchy			Target	Total asset
	fair value	Level 1	Level 2	Level 3	allocation	allocation
Financial assets:						
Investments:						
Short-term investments and						
cash equivalents \$	12	12			%	%
U.S. equity securities	7,308	5,785	1,523		40	40
Debt securities	4,471	3,447	1,024		25	25
International equities	6,376		6,376		35	35
Total assets \$	18,167	9,244	8,923		100%	100%
			201			
	Total	<u>Fai</u>	r value hierarc	hy	Target	Total asset
	fair value	Level 1	Level 2	Level 3	allocation	allocation
Financial assets:						
Investments:						
Short-term investments and						
cash equivalents	S (8)	(8)	_	_	%	%
U.S. equity securities	6,914	5,102	1,812		40	39
Debt securities	4,842	3,433	1,409		25	27
International equities	6,077		6,077		35	34

Cash Flows

Emory University and Emory Healthcare do not expect to contribute to their postretirement healthcare and life insurance benefit plans in 2013. Emory Healthcare plans to fund future retiree claims from VEBA Trust assets.

8,527

9,298

100%

17,825

Expected Future Benefit Payments

Annual future benefit payments are expected to range from \$3.0 million to \$5.0 million for Emory University and from \$1.5 million to \$3.0 million for Emory Healthcare, for the next five years.

Expected Medicare Retiree Drug Subsidies

Medicare retiree drug subsidies for the next five years are expected to be less than \$1.0 million and \$500 thousand annually, for Emory University and Emory Healthcare plans, respectively.

(18) Charity Care and Community Benefits

Emory Healthcare, Inc. and its operating companies provide care to patients who meet certain criteria under their charity care policies without charge or at amounts less than their established rates. Because such operating companies do not pursue collection of amounts determined to qualify as charity care, such amounts are not reported as revenues.

Notes to Consolidated Financial Statements
August 31, 2012 and 2011

Records are maintained to identify and monitor the level of charity care provided. These records include the amount of charges foregone and actual costs for services furnished under its charity and indigent care policies. The cost of charity care provided totaled approximately \$72.1 million and \$67.9 million for the years ended August 31, 2012 and 2011, respectively. The System estimated these costs by applying a ratio of cost to gross charges to the gross uncompensated charges associated with providing care to the charity patients.

As a corporate and community citizen, the System has a community responsibility to increase awareness of health issues affecting community citizens. Part of the commitment to its mission of excellence is in responding to the healthcare needs of residents in its service area. The System offers many wellness and educational services to the community at low and, in some cases, no cost. Health fairs are held throughout the year at convenient locations, providing various health screenings, such as blood pressure and cholesterol checks. A large number of educational programs are offered for all ages. The System operates 24-hour emergency rooms that provide care to all patients regardless of ability to pay. The costs for these services are included in operating expenses in the accompanying consolidated statements of activities.

(19) Grants and Contracts

Grants and contracts from governmental units provide a major portion of funds for research, public service, and other university activities. These grant and contract awards generally specify the purpose for which the funds are to be used.

Federal government grants and contract revenues are generally recognized to the extent that the University incurs actual expenditures under program agreements with federal agencies. These revenues are recorded as unrestricted support. Amounts recorded in federal grants and contracts receivable are for grant expenses incurred in advance of the receipt of funds. Recovery of indirect costs has been recorded based on negotiated rates. Federal funds, together with the indirect costs, are subject to audit by the applicable agencies. In the opinion of management, any adjustment resulting from such audits would not be material to the consolidated financial statements.

Notes to Consolidated Financial Statements August 31, 2012 and 2011

(20) Functional Expenses

The Consolidated Statements of Activities include the following functional expenses for the years ended August 31 (in thousands):

	2012	2011
Instruction \$	365,901	346,008
Research	405,681	410,395
Public service	69,308	61,568
Academic support	119,329	112,854
Student services	72,706	67,349
Institutional support	152,041	154,951
Scholarships and fellowships	12,704	14,085
Medical services	166,500	166,188
Healthcare services	2,427,950	1,971,080
Auxiliary enterprises	38,982	35,271
Independent operations	18,494	20,386
Total operating expenses \$	3,849,596	3,360,135

Costs related to the University's operation and maintenance of property, including depreciation of property and equipment and interest on related debt, are allocated to program and supporting activities based upon information reported in the latest space study and debt financing records. Total amounts allocated in 2012 and 2011 were \$152.9 million and \$138.2 million, respectively. Fundraising costs were approximately \$18.2 million and \$16.0 million in 2012 and 2011, respectively.

(21) Medical Professional and General Liability Insurance Coverage

CCIC, Emory Healthcare's wholly owned off-shore captive insurer, provides claims-made primary medical professional and general liability coverage for the University, the Hospitals, Emory Clinic, Emory Specialty Associates, and Wesley Woods Center. Tail coverage is provided for ECC; effective September 1, 2006, the Emory Children's Center Joint Venture is insured on a stand-alone basis. The CCIC primary program provides limits as follows (in thousands):

		Per clain	Aggregate	
	•	Professional	General	(general only)
September 1, 2011 through August 31, 2012	\$	3,000	1,000	3,000
September 1, 2010 through August 31, 2011	\$	3,000	1,000	3,000

Notes to Consolidated Financial Statements August 31, 2012 and 2011

In excess of the primary professional liability limit of \$3 million per claim, CCIC provides a buffer layer of \$3 million per claim and in the aggregate. Certain Emory Specialty Associate physicians are insured for primary professional liability insurance through MAG Mutual Insurance Company or The Doctor's Company, for limits ranging from \$1 million to \$2 million per claim and \$3 million to \$4 million in the aggregate. These individual policies provide underlying coverage to the CCIC primary limit of \$3 million per claim.

Above the buffer layer, CCIC provides an excess layer of professional liability coverage which is 100% reinsured as follows:

- (1) Berkley Insurance Company (Berkley) reinsures CCIC 100% for a limit of \$15 million per claim and in the aggregate, excess of the buffer layer, excess of the primary layer.
- (2) Continental Casualty Company (CNA) reinsures CCIC 100% for a limit of \$10 million per claim and in the aggregate, excess of the Berkley layer described above.
- (3) Zurich American Insurance Company reinsures CCIC 100% for a limit of \$10 million per claim and in the aggregate, excess of the CAN layer described above.

Emory is insured for excess general liability, employers' liability, international liability, and automobile liability through United Educators which provides a limit of \$35 million per claim excess of an underlying limit of \$1 million per claim and \$3 million in the aggregate for general liability, and \$1 million per claim and in the aggregate for each of employers' liability, international liability and automobile liability.

Emory purchases umbrella coverage, 100% reinsurance of CCIC, in the amount of \$90 million per claim and in the aggregate above the United Educators and Zurich layers described above. The umbrella also provides excess coverage for helipad liability and non-owned aircraft liability, which is purchased commercially, each for a limit of \$25 million per claim in the aggregate.

As of August 31, 2012 and 2011, the University has recorded an accrual for estimated losses associated with all retained CCIC risks of approximately \$102.0 million (discounted at 2%) and \$84.8 million (discounted at 2%), respectively.

The estimated liability for professional and general liability claims will be significantly affected if current and future claims differ from historical trends. While the University monitors reported claims closely and considers potential outcomes as estimated by its actuaries when determining its professional and general liability accruals, the complexity of the claims, the extended period of time to settle the claims and the wide range of potential outcomes complicate the estimation. The University management believes adequate provision has been made for the related risk.

(22) Related-Party Transactions

The Carter Center, Inc. (CCI) is a nonprofit organization founded by former United States President Jimmy Carter which sponsors various domestic and international programs. The board of trustees of CCI is comprised of 22 members, including the University President and 9 other members appointed by the University's board of trustees. The University's board of trustees has the authority to approve amendments to CCI's articles of incorporation and bylaws and to approve the annual and capital budgets of CCI. The

Notes to Consolidated Financial Statements
August 31, 2012 and 2011

University provides minor administrative support to CCI and has an economic interest in CCI but does not exercise control over the organization.

Deposits held in custody for others include \$445.0 million and \$412.9 million representing CCI's investment in the University's long term investment pool as of August 31, 2012 and 2011, respectively.

(23) Acquisition of Joint Venture Interest

On February 28, 2011, the System acquired the 50% interest in EJCH held by its then joint venture partner HCA Holdings, Inc. (HCA). HCA and the System were previously joint venture partners in EHCA, LLC (EHCA), whereby EHCA leased one of HCA's Atlanta-area hospitals, Eastside Medical Center (Eastside), HCA provided operational management of EHCA facilities, and EHC provided medical management and other clinical oversight for EHCA activities.

Consideration for the System's acquisition of HCA's 50% interest in EJCH was comprised of a cash payment of \$60.0 million and the System's ownership interest in the Eastside venture described above. Additionally, the EHCA agreement was dissolved and the unamortized deferred revenue from a related payment made by HCA to the System at inception of the original EHCA agreement, totaling approximately \$5.3 million, was recognized as nonoperating joint venture income in fiscal 2011.

The System recorded a gain on the acquisition totaling approximately \$35.5 million, generally representing the amount by which the fair value of the former HCA interest in EJCH exceeded the acquisition consideration. The gain is included in nonoperating joint venture income in the combined statement of operations in fiscal 2011.

As part of the acquisition transaction, the System also acquired a related medical office building for a cash payment of \$25.0 million, which amount approximated the fair value of the acquired real estate assets.

Notes to Consolidated Financial Statements
August 31, 2012 and 2011

With its acquisition of HCA's 50% interest in EJCH, the System has included the assets, liabilities and operations of EJCH in its combined financial statements, and eliminated its former equity interest in EHCA, from the acquisition date. The following table summarizes the opening balance sheet of EJCH, including the acquired medical office building, at the acquisition date (in thousands):

Cash	\$ 6
Due from HCA - working capital settlement	1,357
Intercompany receivable	6,000
Net patient accounts receivable	11,560
Inventories	3,809
Property and equipment	154,639
Other assets	5,810
Total assets acquired	\$ 183,181
	5.040
Accounts payable and accrued expenses	6,849
Due to third party payors	1,008
Long term debt	85,000
Other long term liabilities	28
Deferred revenue	57
Total liabilities assumed	\$ 92,942
Net assets acquired	\$ 90,239

(24) Formation of Emory/Saint Joseph's, Inc.

Effective December 31, 2011, the System entered into an agreement (the Contribution Agreement) with Saint Joseph's Health System to form a joint operating company under the name of Emory/Saint Joseph's, Inc. The JOC was formed to further the respective missions of the System and Catholic Health East, the sole corporate member of SJHS, to deliver high-quality healthcare services to patients in the North Metro Atlanta area. Under the Contribution Agreement, the System transferred to the JOC the assets and liabilities of EJCH in exchange for a 51% controlling ownership interest in the JOC. SJHS transferred to the JOC the assets and liabilities of SJHA, SJTRI, and SJMG. In addition, on the eighteen month anniversary of the closing date of the transaction, SJHS shall contribute and deliver to the JOC an additional amount in cash of \$5.0 million which amount should be deemed a deferred payment of the SJHS contribution in consideration of the membership interest in the JOC. The Contribution Agreement attributed to SJHS a noncontrolling membership interest in the JOC of 49%.

Notes to Consolidated Financial Statements August 31, 2012 and 2011

The following table summarizes the estimated fair values of the assets acquired and liabilities assumed by the System from SJHS at the date of the transaction (in thousands):

Cash	\$ 71,953
Net patient accounts receivable	40,354
Property, plant and equipment	179,912
Intangible assets	29,200
Other assets	 37,812
Total assets acquired	\$ 359,231
Accounts payable and accrued expenses	42,171
Due to third party payors	4,677
Long term debt	132,942
Accrued pension cost	47,380
Other liabilities	 8,628
Total liabilities assumed	\$ 235,798
Temporarily restricted net assets	\$ 4,768
Unrestricted net assets contributed	\$ 118,665

A summary of EJCH assets and liabilities contributed by the System to the JOC as of December 31, 2011 follows (in thousands):

Cash	\$	8,359
Net patient accounts receiva	able	14,070
Property, plant and equipme	ent	147,115
Intangible assets		5,290
Other assets	_	4,095
Total assets a	acquired \$	178,929
Accounts payable and accru	ed expenses	3,964
Due to third party payors		1,011
Long term debt		83,954
Other liabilities	<u>-</u>	4,582
Total liabiliti	es assumed \$	93,511
Net assets co	ntributed \$	85,418

Because the System retains control of the EJCH assets and liabilities transferred to the JOC, the System did not recognize any gain or loss and measured those assets and liabilities at the carrying amounts immediately before the formation of the JOC.

Notes to Consolidated Financial Statements
August 31, 2012 and 2011

As a result of the formation of the JOC, the System recorded a gain of \$18.7 million representing the difference between the System's 51% interest in the unrestricted net assets of the JOC immediately upon its formation and the net assets of EJCH contributed by the System to the JOC. The gain is included in nonoperating joint venture income in the accompanying combined statement of operations in fiscal 2012.

The fair value of the noncontrolling interest as of December 31, 2011 was \$95.0 million, which is net of the \$5.0 million due from SJHS upon the eighteen month anniversary of the closing of the transaction.

(25) Emory Healthcare – Investment in Partnerships

(a) Emory University Hospital Midtown - CPI, LLC

Emory University Hospital Midtown (EUHM) entered into an equal partnership with Cousins Properties, Inc. (Cousins) to construct and operate a medical office tower (MOT). The MOT was completed and occupied by tenants in 2003, and the property is managed by Cousins.

EUHM has recorded a net liability of \$10.2 million and \$10.7 million as of August 31, 2012 and 2011, respectively, for its portion of partners' deficit, which is included in other long-term liabilities in the accompanying consolidated statements of financial position. The investment in this partnership is accounted for using the equity method of accounting.

(b) Emory-Adventist, Inc.

The University has a 35% joint venture interest in Emory-Adventist, Inc. (Emory-Adventist), which owns and operates Emory-Adventist Hospital in Cobb County, Georgia. EHC has recorded a net liability of \$0.6 million and \$0.4 million as of August 31, 2012 and 2011, respectively, for its portion of the Emory-Adventist unrestricted net deficit, which is included in other long-term liabilities in the accompanying consolidated statements of financial position. The investment in Emory-Adventist is accounted for using the equity method of accounting.

(c) Emory Children's Center, Inc.

The University entered into a joint venture effective November 15, 2006 between Emory Children's Center, Inc. (ECC) and Children's Healthcare of Atlanta (CHOA) to coordinate various aspects of their mutual significant pediatric care operations. The agreement provides the University, through ECC, a 51% financial interest in the venture known as ECC and provides that CHOA will fund 50% of the total losses of the joint venture. The financial position of the venture and the results of its operations are consolidated with ECC's financial position and results of operations in the accompanying consolidated financial statements.

Effective July 1, 2013, the joint venture agreement with CHOA will be terminated, and all pediatric care operations will become the responsibility of CHOA.

(26) Commitments and Contingencies

The University is in the process of constructing, renovating and equipping certain facilities for which the outstanding commitments at August 31, 2012 totaled \$70.1 million. At August 31, 2011, commitments totaled \$82.3 million.


Notes to Consolidated Financial Statements
August 31, 2012 and 2011

Lawsuits and claims have been filed against the University in the ordinary course of business. As one of the nation's largest research universities and academic medical centers, the University has active litigation that takes several forms. The University's policy is to accrue for litigation and claims when such amounts are probable and can be reasonably estimated based on consultation with external legal counsel and Emory General Counsel review. In addition, the University is subject to many federal and state regulations and, as a result, there may be one or more pending government investigations ongoing at any time. While the outcome of many of these actions is not presently determinable, it is the opinion of management that any resulting liability from these actions will not have a material adverse effect on the consolidated financial position or operating results of the University. The University also has a comprehensive program of primary and excess insurance, if a final judgment were entered in any action in excess of its insurance coverage; the University would be liable for the excess. Management of the University believes that no currently pending lawsuit subjecting the University to liability would have a materially adverse effect on the University's consolidated financial position.

(27) Subsequent Events

On October 1, 2012, the System entered into an agreement with Southern Regional Health System (SRHS) to provide management services for a five year period. The System will be responsible for the day to day operations of SRHS, as further defined in the agreement, and will be paid a fee equal to the cost of services provided plus 2% in the first 2 years, escalating to 3% in the fifth year. The Board of SRHS retains control of SRHS, including approval of budgets, certain capital expenditures, and issuance of debt.

The University has evaluated its subsequent events (events occurring after August 31, 2012) through January 15, 2013, which represents the date the consolidated financial statements were issued and determined that all significant events and disclosures are included in the consolidated financial statements.



EMORY UNIVERSITY (excluding Emory Healthcare) STATEMENTS OF FINANCIAL POSITION - INFORMATION

August 31, 2012 and 2011

(Dollars in thousands)

2012		2012	2011		
ASSETS:					
Cash and cash equivalents	\$	381,908	\$	300,983	
Student accounts receivable, net		43,776		35,969	
Loans receivable, net		26,777		27,724	
Contributions receivable, net		156,647		175,169	
Accrued investment income receivable		4,978		7,030	
Other receivables, net		155,689		204,020	
Prepaid expenses, deferred charges and other assets		159,478		117,806	
Investments		5,454,156		5,194,900	
Interests in perpetual funds held by others		1,025,848		965,613	
Property and equipment, net		1,804,919		1,769,826	
Due from affiliates		731,590		456,163	
Total assets	\$	9,945,766	\$	9,255,203	
LIABILITIES AND NET ASSETS:					
Accounts payable and accrued liabilities	\$	157,498	\$	156,204	
Liability for derivative instruments		215,041		140,173	
Interest payable		27,489		22,750	
Annuities payable		18,052		19,047	
Bonds, notes and mortgages payable		1,877,355		1,786,034	
Accrued liabilities for benefit obligations and professional liabilities		68,031		55,358	
Deferred tuition and other revenue		385,985		343,306	
Deposits held in custody for others		476,915		465,776	
Government advances for federal loan programs		17,820		17,499	
Due to affiliates		373,278		220,457	
Total liabilities		3,617,464		3,226,604	
Unrestricted net assets		2,240,943		2,152,293	
Temporarily restricted net assets		2,518,037		2,382,428	
Permanently restricted net assets		1,569,322		1,493,878	
Total net assets		6,328,302		6,028,599	
Total liabilities and net assets	\$	9,945,766	\$	9,255,203	

See accompanying independent auditors' report.

STATEMENT OF ACTIVITIES - INFORMATION

Year ended August 31, 2012 (with summarized financial inforantion for the year ended 2011)

Less Scholarship allowances (183.783)	(Dollars in thousands)	Unrestricted	Temporarily Restricted	Permanently Restricted	Total August 31, 2012	Total August 31, 2011
Less: Scholumbin allowances CHS1783 - CHS1785 CH5728 CH5	OPERATING REVENUES:					
Net utilizion and fees	Tuition and fees	\$ 512,680	-	-	\$ 512,680	\$ 483,251
Endowment spending distribution	Less: Scholarship allowances	(183,783)			(183,783)	(167,285)
Other investment income designated for current operations 49,741 - 49,741 30,58 Giffis and contributions 42,639 - 42,639 38,18 Indirect cost recoveries 122,728 - 122,728 122,728 Ginnts and contracts 382,391 - 382,391 374,66 Medical services of auxiliary operating activities 63,087 - 63,087 57,70 6,81 Sales and services of auxiliary operating activities 63,087 - 5,760 6,81 22,138 22,118 22,118 22,118 22,118 22,118 22,118 22,118 22,118 22,118 22,118 22,118 22,118 22,118 22,118 22,118 22,118 22,113 22,118 22,118 22,118 22,118 22,118 22,118 22,118 22,118 22,118 22,118 22,118 22,118 22,133 22,133 23,133 22,133 22,133 22,133 22,133 22,133 22,133 22,133 22,134 13,184 42,29	Net tuition and fees	328,897	-	-	328,897	315,966
Gifs and contributions	Endowment spending distribution	176,541	-	-	176,541	169,533
Indirect cost recoveries	Other investment income designated for current operations	49,741	-	-	49,741	30,583
Grants and contracts 382.391 . 382.391 374.63 Medicial services 147,430 147,430 Medicial services of auxiliary operating activities 63,087 . . . Sakes and services of auxiliary operating activities 22,138 . . . Independent operations 22,138 Deficial partial prevenue 33,884 . . Sake and services of auxiliary operating activities 33,884 . . . The anten and rayslay revenue 33,884 . . . The anten and rayslay revenue 33,884 . . Total operating revenues 1,378,917 (3,681) Total operating revenues 1,378,917 (3,681) Total operating revenues 1,378,917 (3,681) . . . Total operating revenues 1,378,917 (3,681) . . . Salaries and fringe benefits 1,004,775 . . Salaries and fringe benefits 1,004,775 . . Subdent financial aid 9,297 Other operating expenses 251,333	Gifts and contributions	42,639	-	-	42,639	38,169
Medical services 147,430 138,36 138,36 136,368 136,3687 147,430 138,36 138,36 136,3687 147,430 138,36 136,3687 147,430 138,36 136,3687 147,430 138,36 136,3687 147,430 138,36 136,3687 147,430 138,368 147,368 147,368 147,430	Indirect cost recoveries	122,728	-	-	122,728	122,378
Sales and services of auxiliary operating activities 63,087 - 63,087 57,74 Independent operations 22,138 - 22,138 21,11 Patent and royally revenue 3,760 - 3,760 33,884 42,93 Other revenue 33,884 3,681 - - 33,884 42,93 Net assets released from restrictions 3,881 3,681 - 1,275,236 1,318,23 Total operating revenues 1,378,917 3,681 - 1,275,236 1,318,23 OPERATING EXPENSES: Salaries and fringe benefits 1,004,775 - 1,004,775 964,02 Suddent financial aid 9,297 - 9,297 10,64 Other operating expenses 251,333 - 251,333 25,133 25,133 25,133 25,133 25,123 10,64 10,71,68 10,71,68 10,72,74 10,71,68 10,72,74 10,71,68 10,72,74 10,71,68 10,72,74 10,74,64 13,28,08 10,72,74 10,74,76<	Grants and contracts	382,391	-	-	382,391	374,630
Independent operations	Medical services	147,430	-	-	147,430	138,364
Patent and royally revenue	Sales and services of auxiliary operating activities	63,087	-	-	63,087	57,743
Other revenue 33,884 - - 33,884 42,93 Net assets released from restrictions 1,378,917 (3,681) - - - - Total operating revenues 1,378,917 (3,681) - 1,375,236 1,318,23 OPERATING EXPENSES: 3 1,004,775 - - 1,004,775 964,02 Student financial aid 9,297 - - 9,297 10,64 Other operating expenses 251,333 - - 251,333 255,41 Interest on includebudness 49,073 - - 107,168 102,74 Depreciation 107,168 - - 107,168 102,74 Total operating expenses 1,421,646 - - 1,421,646 1,389,05 NET OPERATING REVENUES/(EXPENSES): (42,729) (3,681) - 1,421,646 1,389,05 Net unealized gains on investments 20,057 30,445 54,385 104,887 265,50 Investment income and gains (losses) in excess o	Independent operations	22,138	-	-	22,138	21,119
Net assets released from restrictions	Patent and royalty revenue	5,760	-	-	5,760	6,819
Total operating revenues	Other revenue	33,884	-	-	33,884	42,935
OPERATING EXPENSES: Salaries and fringe benefits 1,004,775 - 1,004,775 964,02 Student financial aid 9,297 - 9,297 10,64 Other operating expenses 251,333 - 251,333 255,43 Interest on indebtedness 49,073 - 49,073 56,22 Depreciation 107,168 - 107,168 102,74 Total operating expenses 1,421,646 - - 1,421,646 1,389,05 NET OPERATING REVENUES/(EXPENSES): (42,729) (3,681) - (46,410) (70,81 NONOPERATING ACTIVITIES: 0 0 0 1,421,646 - 1,421,646 1,438,05 1,438,05 1,448,06 1,438,05 1,448,06	Net assets released from restrictions	3,681	(3,681)	-	-	-
Salaries and fringe benefits	Total operating revenues	1,378,917	(3,681)		1,375,236	1,318,239
Student financial aid 9,297 -	OPERATING EXPENSES:					
Student financial aid 9,297 -	Salaries and fringe benefits	1,004,775	-	-	1,004,775	964,023
Interest on indebtedness	•	9,297	-	-	9,297	10,649
Interest on indebtedness	Other operating expenses	251,333	-	-	251,333	255,414
Depreciation		49.073	_	_	49.073	56,223
NET OPERATING REVENUES/(EXPENSES): (42,729) (3,681) - (46,410) (70,810) NONOPERATING ACTIVITIES: Net unrealized gains on investments 20,057 30,445 54,385 104,887 266,500 Investment income and gains (losses) in excess of spending distribution for current operations Investment management fees (18,778) (176) (124) (19,078) (23,880 fifs and contributions 9,939 72,368 18,561 100,368 54,460 Loss (gain) on disposal of property and equipment (11,517) (11,517) 23 Gain on defeasance of debt (14,688) 13,370 Other nonoperating items (74,868) (74,868) 13,370 Other nonoperating items (4,265) (701) (410) (5,376) (43,520 fits and operating activities 83,226 83,226 80,840 CHANGE IN NET ASSETS 88,650 135,609 75,444 299,703 564,555 BEGINNING NET ASSETS 2,152,293 2,382,428 1,493,878 6,028,599 5,464,040 decreases the control of the control operating activities (42,259) 5,464,040 decreases the control operating activities (42,259) 5,464,040 decreases the control operating activities (42,259) 5,464,040 decreases the control operating activities (42,269) 6,464,040 decreases the control operating activities (42,269) decreases the control operating activiti			-	-		102,746
NONOPERATING ACTIVITIES: Net unrealized gains on investments Investment income and gains (losses) in excess of spending distribution for current operations Investment management fees	Total operating expenses	1,421,646			1,421,646	1,389,055
Net unrealized gains on investments 20,057 30,445 54,385 104,887 266,50 Investment income and gains (losses) in excess of spending distribution for current operations 127,585 37,354 3,032 167,971 285,10 Investment management fees (18,778) (176) (124) (19,078) (23,88 Gifts and contributions 9,939 72,368 18,561 100,868 54,46 Loss (gain) on disposal of property and equipment (11,517) - - (11,517) 23 Gain on defeasance of debt - - - - - 2,25 Change in fair value of derivative instruments (74,868) - - (74,868) 13,37 Other nonoperating activities 48,153 139,290 75,444 262,887 554,52 Net transfers from affiliates 83,226 - - - 83,226 80,84 CHANGE IN NET ASSETS 88,650 135,609 75,444 299,703 564,55 BEGINNING NET ASSETS 2,152,293 2,382,428	NET OPERATING REVENUES/(EXPENSES):	(42,729)	(3,681)		(46,410)	(70,816)
Investment income and gains (losses) in excess of spending distribution for current operations 127,585 37,354 3,032 167,971 285,102	NONOPERATING ACTIVITIES:					
Investment income and gains (losses) in excess of spending distribution for current operations 127,585 37,354 3,032 167,971 285,102	Net unrealized gains on investments	20,057	30,445	54,385	104,887	266,500
distribution for current operations Investment management fees (18,778) (176) (124) (19,078) (23,88 Gifts and contributions 9,939 72,368 18,561 100,868 54,46 Loss (gain) on disposal of property and equipment (11,517) - - (11,517) 23 Gain on defeasance of debt - - - - 2,25 Change in fair value of derivative instruments (74,868) - - (74,868) 13,37 Other nonoperating items (4,265) (701) (410) (5,376) (43,52 Total nonoperating activities 48,153 139,290 75,444 262,887 554,52 Net transfers from affiliates 83,226 - - - 83,226 80,84 CHANGE IN NET ASSETS 88,650 135,609 75,444 299,703 564,55 BEGINNING NET ASSETS 2,152,293 2,382,428 1,493,878 6,028,599 5,464,04						285,106
Investment management fees (18,778) (176) (124) (19,078) (23,88 Gifts and contributions 9,939 72,368 18,561 100,868 54,46 Loss (gain) on disposal of property and equipment (11,517) - - (11,517) 23 Gain on defeasance of debt - - - - - 2,25 Change in fair value of derivative instruments (74,868) - - (74,868) 13,37 Other nonoperating items (4,265) (701) (410) (5,376) (43,52 Total nonoperating activities 48,153 139,290 75,444 262,887 554,52 Net transfers from affiliates 83,226 - - - 83,226 80,84 CHANGE IN NET ASSETS 88,650 135,609 75,444 299,703 564,55 BEGINNING NET ASSETS 2,152,293 2,382,428 1,493,878 6,028,599 5,464,04						
Gifts and contributions 9,939 72,368 18,561 100,868 54,46 Loss (gain) on disposal of property and equipment (11,517) - - (11,517) 23 Gain on defeasance of debt - - - - - 2,25 Change in fair value of derivative instruments (74,868) - - (74,868) 13,37 Other nonoperating items (4,265) (701) (410) (5,376) (43,52) Total nonoperating activities 48,153 139,290 75,444 262,887 554,52 Net transfers from affiliates 83,226 - - 83,226 80,84 CHANGE IN NET ASSETS 88,650 135,609 75,444 299,703 564,55 BEGINNING NET ASSETS 2,152,293 2,382,428 1,493,878 6,028,599 5,464,04	•	(18,778)	(176)	(124)	(19,078)	(23,886
Loss (gain) on disposal of property and equipment (11,517) - - (11,517) 23 Gain on defeasance of debt - - - - 2,25 Change in fair value of derivative instruments (74,868) - - (74,868) 13,37 Other nonoperating items (4,265) (701) (410) (5,376) (43,52 Total nonoperating activities 48,153 139,290 75,444 262,887 554,52 Net transfers from affiliates 83,226 - - 83,226 80,84 CHANGE IN NET ASSETS 88,650 135,609 75,444 299,703 564,55 BEGINNING NET ASSETS 2,152,293 2,382,428 1,493,878 6,028,599 5,464,04	_		` '			54,469
Gain on defeasance of debt - - - - 2,25 Change in fair value of derivative instruments (74,868) - - (74,868) 13,37 Other nonoperating items (4,265) (701) (410) (5,376) (43,52) Total nonoperating activities 48,153 139,290 75,444 262,887 554,52 Net transfers from affiliates 83,226 - - 83,226 80,84 CHANGE IN NET ASSETS 88,650 135,609 75,444 299,703 564,55 BEGINNING NET ASSETS 2,152,293 2,382,428 1,493,878 6,028,599 5,464,04			-	-		232
Change in fair value of derivative instruments (74,868) - - (74,868) 13,37 Other nonoperating items (4,265) (701) (410) (5,376) (43,52) Total nonoperating activities 48,153 139,290 75,444 262,887 554,52 Net transfers from affiliates 83,226 - - 83,226 80,84 CHANGE IN NET ASSETS 88,650 135,609 75,444 299,703 564,55 BEGINNING NET ASSETS 2,152,293 2,382,428 1,493,878 6,028,599 5,464,04		-	_	_		2,255
Other nonoperating items (4,265) (701) (410) (5,376) (43,52) Total nonoperating activities 48,153 139,290 75,444 262,887 554,52 Net transfers from affiliates 83,226 - - 83,226 80,84 CHANGE IN NET ASSETS 88,650 135,609 75,444 299,703 564,55 BEGINNING NET ASSETS 2,152,293 2,382,428 1,493,878 6,028,599 5,464,04		(74.868)	_	_	(74.868)	13,370
Net transfers from affiliates 83,226 - - 83,226 83,226 - - 83,226 80,84 CHANGE IN NET ASSETS 88,650 135,609 75,444 299,703 564,55 BEGINNING NET ASSETS 2,152,293 2,382,428 1,493,878 6,028,599 5,464,04			(701)	(410)		(43,525)
CHANGE IN NET ASSETS 88,650 135,609 75,444 299,703 564,55 BEGINNING NET ASSETS 2,152,293 2,382,428 1,493,878 6,028,599 5,464,04	Total nonoperating activities	48,153	139,290	75,444	262,887	554,521
BEGINNING NET ASSETS 2,152,293 2,382,428 1,493,878 6,028,599 5,464,04	Net transfers from affiliates	83,226	-	-	83,226	80,849
	CHANGE IN NET ASSETS	88,650	135,609	75,444	299,703	564,554
ENDING NET ASSETS \$ 2,240,943 \$ 2,518,037 \$ 1,569,322 \$ 6,328,302 \$ 6,028,59	BEGINNING NET ASSETS	2,152,293	2,382,428	1,493,878	6,028,599	5,464,045
	ENDING NET ASSETS	\$ 2,240,943	\$ 2,518,037	\$ 1,569,322	\$ 6,328,302	\$ 6,028,599

See accompanying independent auditors' report.

EMORY UNIVERSITY (excluding Emory Healthcare)

STATEMENT OF ACTIVITIES - INFORMATION

Year Ended August 31, 2011

(Dollars in thousands)	Unrestricted	Temporarily Restricted	Permanently Restricted	Total
OPERATING REVENUES:				
Tuition and fees	\$ 483,251	-	-	\$ 483,251
Less: Scholarship allowances	(167,285)			(167,285)
Net tuition and fees	315,966	-	-	315,966
Endowment spending distribution	169,533	-	-	169,533
Other investment income designated for current operations	30,583	-	-	30,583
Gifts and contributions	38,169	-	-	38,169
Indirect cost recoveries	122,378	-	-	122,378
Grants and contracts	374,630	-	-	374,630
Medical services	138,364	-	-	138,364
Sales and services of auxiliary operating activities	57,743	-	-	57,743
Independent operations	21,119	-	-	21,119
Patent and royalty revenue	6,819	-	-	6,819
Other revenue	42,935	-	-	42,935
Net assets released from restrictions	5,935	(5,935)		
Total operating revenues	1,324,174	(5,935)	::::::::::::::::::::::::::::::::::::::	1,318,239
OPERATING EXPENSES:				
Salaries and fringe benefits	964,023	_	_	964,023
Student financial aid	10,649	_	_	10,649
Other operating expenses	255,414	_	_	255,414
Interest on indebtedness	56,223	_	_	56,223
Depreciation Depreciation	102,746	_	_	102,746
		-1		
Total operating expenses	1,389,055	<u> </u>	<u>-1-1-1-1-1-1-1-1-1-</u>	1,389,055
NET OPERATING REVENUES/(EXPENSES):	(64,881)	(5,935)		(70,816)
NONOPERATING ACTIVITIES:				
Net unrealized gains on investments	26,397	57,781	182,322	266,500
Investment income and gains (losses) in excess of spending distribution for current operations	155,559	128,559	988	285,106
Investment management fees	(23,557)	(168)	(161)	(23,886)
Gifts and contributions	26,722	13,954	13,793	54,469
Gain on disposal of property and equipment	232	-	-	232
Gain on defeasance of debt	2,255	-	-	2,255
Change in fair value of derivative instruments	13,370	_	_	13,370
Other nonoperating items	(38,676)	(2,053)	(2,796)	(43,525)
Total nonoperating activities	162,302	198,073	194,146	554,521
Net transfers from affiliates	80,849	-	-	80,849
CHANGE IN NET ASSETS	178,270	192,138	194,146	564,554
BEGINNING NET ASSETS	1,974,023	2,190,290	1,299,732	5,464,045
ENDING NET ASSETS	\$ 2,152,293	\$ 2,382,428	\$ 1,493,878	\$ 6,028,599

See accompanying independent auditors' report.

EMORY UNIVERSITY (excluding Emory Healthcare) STATEMENTS OF CASH FLOWS - INFORMATION

Years Ended August 31, 2012 and 2011

(Dollars in thousands)

CASH ELOWS EDOM ODED ATING A CONTINUES		<u>2012</u>		<u>2011</u>
CASH FLOWS FROM OPERATING ACTIVITIES: Change in net assets	\$	299,703	\$	564,554
Adjustments to reconcile change in net assets to net cash		,		,
used in operating activities:				
Nonoperating items:				
Gifts restricted for long-term investment and capital projects		(109,351)		(17,681)
Net realized gain on sale of investments		(288,734)		(404,680)
Loss (gain) on disposal of property and equipment		11,517		(232)
Interests in perpetual funds held by others		(60,235)		(184,421)
Gain on defeasance of debt		(00,233)		(2,255)
Noncash items:		_		(2,233)
Depreciation		107,168		102,746
-		*		(15,802)
Accretion/amortization of bond discounts/premiums		(3,324) (91,033)		(82,959)
Net unrealized gains on investments Change in fair value of derivative instruments				
Gifts of securities and other assets		74,868		(13,370)
		(62,642)		(34,884)
(Increase) decrease in:		40.524		(70,502)
Accounts receivable, net		40,524		(78,583)
Contributions receivable		18,522		(9,604)
Accrued investment income receivable		2,052		(520)
Prepaid expenses, deferred charges and other assets		(1,653)		(10,167)
Due to/from affiliates		(122,606)		(74,927)
Increase (decrease) in:				
Accounts payable and interest payable		(13,366)		37,721
Accrued liabilities for benefit obligations and professional liabilities		12,673		(10,924)
Deferred tuition and other revenue		42,679	_	(5,188)
Net cash used in operating activities		(143,238)	_	(241,176)
CASH FLOWS FROM INVESTING ACTIVITIES:				
Disbursements of loans to students		(3,879)		(3,203)
Repayment of loans from students		4,825		4,990
Proceeds from sales and maturities of investments		9,058,186		6,662,170
Purchases of investments		(8,875,033)		(6,320,094)
Purchases of property, plant and equipment		(134,379)		(101,146)
Increase in deposits held in custody for others		11,139		47,702
Net cash provided by investing activities		60,860	_	290,419
- · · · · · · · · · · · · · · · · · · ·	-		_	
CASH FLOWS FROM FINANCING ACTIVITIES:				
Gifts restricted for long-term investment and capital projects		109,351		17,681
Proceeds from bonds and mortgages payable		132,150		229,185
Principal repayments of bonds and mortgages payable		(37,505)		(261,791)
Required posting of collateral		(40,691)		
Decrease in annuities payable		(995)		(213)
Increase (decrease) in government advances for federal loan programs		321		(285)
Bond issuance costs		672	_	(270)
Net cash provided by (used in) financing activities		163,303		(15,693)
Net increase in cash and cash equivalents		80,925		33,550
Cash and cash equivalents at beginning of year		300,983		267,433
Cash and cash equivalents at end of year	\$	381,908	\$_	300,983